<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0054">
    <title>37 Haemophilus</title>
    <sect1 id="ch0054s0001">
      <title>37 Haemophilus</title>
      <anchor id="ch0054s0001a0001"/>
      <anchor id="ch0054s0001a0002"/>
      <para role="chapterAuthor"><phrase role="center">MARK D. GONZALEZ AND NATHAN A. LEDEBOER</phrase>
      </para>
      <sect2 id="ch0054s0001s0001">
        <title>TAXONOMY AND DESCRIPTION OF THE GENUS</title>
        <anchor id="ch0054s0001s0001a0001"/>
        <anchor id="ch0054s0001s0001a0002"/>
        <para id="ch0054s0001s0001p0001"><emphasis>Haemophilus</emphasis> spp. are members of the family <emphasis>Pasteurellaceae</emphasis> (<link linkend="ch0054s0019s0002li0001">1</link>). While the number of <emphasis>Haemophilus</emphasis> spp. described greatly exceeds the number of human pathogens, eight species affecting humans currently included in this genus are <emphasis>Haemophilus influenzae, H. aegyptius, H. ducreyi, H. pittmaniae, H. parainfluenzae, H. haemolyticus, H. parahaemolyticus</emphasis>, and <emphasis>H. paraphrohaemolyticus.</emphasis> Other species have been reported to colonize humans without reports of disease, including the recently described <emphasis>H. seminalis</emphasis> sp. nov., which has been isolated from human semen specimens and closely clusters with <emphasis>H. haemolyticus</emphasis> (<link linkend="ch0054s0019s0002li0002">2</link>), and <emphasis>H. sputorum</emphasis>, which was isolated from blood and sputum of cystic fibrosis patients and from sockets of extracted teeth. Similar to <emphasis>H. seminalis, H. sputorum</emphasis> forms a unique cluster with the closely related <emphasis>H. paraphrohaemolyticus</emphasis> (<link linkend="ch0054s0019s0002li0003">3</link>). <emphasis>Aggregatibacter aphrophilus, Aggregatibacter paraphrophilus</emphasis>, and <emphasis>Aggregatibacter segnis</emphasis> were formerly included in the genus <emphasis>Haemophilus</emphasis> but have been reclassified into the genus <emphasis>Aggregatibacter</emphasis> (formerly <emphasis>Actinobacillus</emphasis>) based on molecular taxonomy (<link linkend="ch0054s0019s0002li0004">4</link>). Additionally, <emphasis>A. aphrophilus</emphasis> and <emphasis>A. paraphrophilus</emphasis> have been combined into a single species, <emphasis>A. aphrophilus</emphasis>, with some representative strains being reassigned to the genus <emphasis>Avibacterium</emphasis> (<link linkend="ch0054s0019s0002li0004">4</link>, <link linkend="ch0054s0019s0002li0005">5</link>). A description of the characteristics and epidemiology of the reclassified <emphasis>A. aphrophilus</emphasis> species group can be found in <link linkend="ch0054s0001">chapter 37</link> of this <emphasis>Manual</emphasis>.</para>
        <para id="ch0054s0001s0001p0002">Even given the reclassification of species, significant genetic diversity exists in the genus<emphasis>Haemophilus.</emphasis> The genomes of these species range in size from 1.8 Mb for <emphasis>H. influenzae</emphasis> to 2.8 Mb for <emphasis>H. ducreyi</emphasis> (<link linkend="ch0054s0019s0002li0006">6</link>). DNA-DNA hybridization studies have demonstrated heterogeneity between species; studies conducted by Burbach et al., as discussed in reference <link linkend="ch0054s0019s0002li0007">7</link>, demonstrate binding ratios between <emphasis>H. influenzae</emphasis> and other species to range from 10% (<emphasis>H. paracuniculus</emphasis>) to 70% (<emphasis>H. aegyptius</emphasis>). As demonstrated in <anchor id="ch0054s0001s0001a0003"/><link linkend="ch0054s0001s0001a0005">Fig. 1</link>, <emphasis>H. influenzae</emphasis> is most closely related to <emphasis>H. aegyptius</emphasis>, with 90% homology, and most distant from <emphasis>H. ducreyi</emphasis>, with only 18% homology. Intraspecies heterogeneity is also significant, ranging from 50 to 100% among <emphasis>H. influenzae</emphasis> and <emphasis>H. parainfluenzae</emphasis> strains (<link linkend="ch0054s0019s0002li0006">6</link>).</para>
        <para id="ch0054s0001s0001p0003">Members of the<emphasis>Haemophilus</emphasis> genus are small, nonmotile, non-spore-forming, non-acid-fast, pleomorphic, Gram-negative bacilli with fastidious growth requirements. Cells in this genus are coccobacilli or short rods. The cell wall resembles those of other Gram-negative bacilli but contains fewer fatty acids than occur in other members of the family <emphasis>Pasteurellaceae</emphasis>; the lipopolysaccharide of <emphasis>Haemophilus</emphasis> is structurally different from those of members of the <emphasis>Enterobacterales</emphasis> (<link linkend="ch0054s0019s0002li0001">1</link>, <link linkend="ch0054s0019s0002li0006">6</link>, <link linkend="ch0054s0019s0002li0007">7</link>). Fatty acid composition of the cell wall includes <emphasis>n-</emphasis>tetradecanoate (14:0), 3-hydroxy-tetradecanoate (3-OH-14:0), <emphasis>n-</emphasis>hexadecanoate (16:0), and hexadecanoate (16:1) (<link linkend="ch0054s0019s0002li0008">8</link>). Fimbriae have been observed on the cell walls of certain strains of <emphasis>H. influenzae</emphasis> and <emphasis>H. aegyptius</emphasis> (<link linkend="ch0054s0019s0002li0006">6</link>). The genome of <emphasis>Haemophilus</emphasis> spp. is characterized by a G+C content of 37 to 45% (<link linkend="ch0054s0019s0002li0001">1</link>, <link linkend="ch0054s0019s0002li0006">6</link>, <link linkend="ch0054s0019s0002li0009">9</link>).</para>
        <para id="ch0054s0001s0001p0004"><emphasis>Haemophilus</emphasis> spp. are facultatively anaerobic, with requirements for X and/or V factor for growth. X factor is protoporphyrin IX, a metabolic intermediate in the hemin biosynthetic pathway (<link linkend="ch0054s0019s0002li0006">6</link>). V factor is composed of nicotinamide complexed as NAD or NADP. Both factors are present in erythrocytes (<emphasis>Haemophilus</emphasis> means “blood loving” in Greek). Requirements for these compounds vary based on the species, with <emphasis>H. influenzae, H. aegyptius</emphasis>, and <emphasis>H. haemolyticus</emphasis> requiring both X and V factors for growth and others requiring only a single factor. Most other clinically significant <emphasis>Haemophilus</emphasis> species require V factor only, while <emphasis>H. ducreyi</emphasis> requires X factor (<anchor id="ch0054s0001s0001a0004"/><link linkend="ch0054s0001s0002a0004">Table 1</link>). Optimal growth occurs at 35 to 37°C in the presence of 5 to 7% CO<subscript>2.</subscript> <emphasis>H. influenzae, H. aegyptius, H. ducreyi, H. pittmaniae, H. parainfluenzae, H. haemolyticus, H. parahaemolyticus, H. paraphrohaemolyticus</emphasis>, and <emphasis>H. sputorum</emphasis> are oxidase positive. <emphasis>H. influenzae, H. aegyptius, H. haemolyticus</emphasis>, and <emphasis>H. paraphrohaemolyticus</emphasis> are catalase positive. <emphasis>H. parainfluenzae, H. parahaemolyticus</emphasis>, and <emphasis>H. segnis</emphasis> exhibit a catalase reaction that is strain dependent (<link linkend="ch0054s0019s0002li0001">1</link>).</para>
        <para id="ch0054s0001s0001p0005">Organisms within the genus<emphasis>Haemophilus</emphasis> typically grow on chocolate agar, producing colonies that are usually smooth, with a flat or convex shape. They are nonpigmented (i.e., buff or light tan) or slightly yellow and are 0.5 to 2.0 mm in diameter. Certain <emphasis>Haemophilus</emphasis> spp. produce beta-hemolysis when grown on sheep blood agar plates (<link linkend="ch0054s0001s0002a0004">Table 1</link>).</para>
        <figure id="ch0054s0001s0001f0001"><title><phrase role="figureLabel"><anchor id="ch0054s0001s0001a0005"/><link linkend="ch0054s0001s0001a0003">FIGURE 1</link></phrase> Phylogenetic tree of <emphasis>Haemophilus</emphasis> species.</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0054f11.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <para id="ch0054s0001s0001p0006">Species of<emphasis>Haemophilus</emphasis> other than <emphasis>H. ducreyi</emphasis> typically ferment a wide range of biochemical substrates. In particular, fermentation of glucose, sucrose, lactose, mannose, and xylose is a set of useful characteristics in the species identification of organisms in this genus. Production of indole, ornithine decarboxylase, urease, catalase, and β-galactosidase plus the ability to produce beta-hemolysis on blood-containing media represents another set of variable properties of <emphasis>Haemophilus</emphasis> spp. that aid in the species identification of organisms in this genus (<link linkend="ch0054s0001s0002a0004">Table 1</link>).</para>
        <anchor id="ch0054s0001s0001a0006"/>
        <beginpage pagenum="729"/>
        <para id="ch0054s0001s0001p0007">Strains of<emphasis>H. influenzae</emphasis> may produce one of six distinct capsular polysaccharides or may be nonencapsulated. Nonencapsulated <emphasis>H. influenzae</emphasis> strains are referred to as nontypeable <emphasis>H. influenzae</emphasis> (NTHi) (<link linkend="ch0054s0019s0002li0010">10</link>) (<anchor id="ch0054s0001s0001a0007"/><link linkend="ch0054s0001s0002a0017">Fig. 2</link>). The presence of polysaccharide capsular antigen provides the basis for serotype designations, a to f. Capsular serotyping is based on polysaccharide composition of the capsular structure. Depending on the strain type, the capsule is composed of ribose and fructose in the furanose ring and glucose (Glc), galactose (Gal), <emphasis>N</emphasis>-acetylglucosamine (GlcNAc), or <emphasis>N</emphasis>-acetylmannosamine uronic acid (ManANAc) in the pyranose ring. Structures of capsules belonging to each serotype can be found in reference (<link linkend="ch0054s0019s0002li0007">7</link>). Within public health laboratories or laboratories without mass spectrometry-based identification systems; indole, ornithine decarboxylase, and urease production is the basis for a biotyping scheme with both <emphasis>H. influenzae</emphasis> and <emphasis>H. parainfluenzae</emphasis> (<link linkend="ch0054s0019s0002li0011">11</link>) (<anchor id="ch0054s0001s0001a0008"/><link linkend="ch0054s0001s0002a0019">Table 2</link>).</para>
      </sect2>
      <sect2 id="ch0054s0001s0002">
        <title>EPIDEMIOLOGY AND TRANSMISSION</title>
        <anchor id="ch0054s0001s0002a0001"/>
        <anchor id="ch0054s0001s0002a0002"/>
        <para id="ch0054s0001s0002p0001"><emphasis>Haemophilus</emphasis> spp. can be found as part of the commensal microbiota of mucous membranes in humans. Colonization of the oral cavity superior to the palatal arches by <emphasis>H. parainfluenzae</emphasis> and <emphasis>H. pittmaniae</emphasis> is normal (<link linkend="ch0054s0019s0002li0006">6</link>, <link linkend="ch0054s0019s0002li0012">12</link>–<link linkend="ch0054s0019s0002li0015">15</link>). <emphasis>H. parahaemolyticus</emphasis> and <emphasis>H. haemolyticus</emphasis> colonization in healthy individuals is rare, although <emphasis>H. haemolyticus</emphasis> has been isolated from subgingival dental plaques (<link linkend="ch0054s0019s0002li0006">6</link>). Colonization of the cervix with <emphasis>H. ducreyi</emphasis> following sexual intercourse has been documented (<link linkend="ch0054s0019s0002li0016">16</link>, <link linkend="ch0054s0019s0002li0017">17</link>).</para>
        <para id="ch0054s0001s0002p0002"><emphasis>H. influenzae</emphasis> may also be found as part of the commensal bacterial microbiota of the mucosal surfaces of the upper respiratory tract (URT) of many healthy individuals (<link linkend="ch0054s0019s0002li0018">18</link>); however, asymptomatic colonization of the URT with encapsulated strains of <emphasis>H. influenzae</emphasis> type b (Hib) is rare. Carriage of Hib was reported in only 2 to 5% of healthy children in the prevaccine era and has decreased by 99% since the introduction of the pediatric Hib conjugate antigen vaccine, HIB, in the 1980s (<link linkend="ch0054s0019s0002li0019">19</link>, <link linkend="ch0054s0019s0002li0020">20</link>). In contrast, NTHi, together with strains of <emphasis>H. parainfluenzae</emphasis>, represents a major portion of the cultured bacterial microbiota of the pharynx and nasopharynx of &gt;90% of healthy individuals (<link linkend="ch0054s0019s0002li0013">13</link>, <link linkend="ch0054s0019s0002li0021">21</link>). Clones of NTHi present in the URT differ when asymptomatic carriers are compared to those with infection (<link linkend="ch0054s0019s0002li0021">21</link>, <link linkend="ch0054s0019s0002li0022">22</link>). In asymptomatically colonized individuals, clones vary continuously, with a mean duration of carriage of 1 to 2 months (<link linkend="ch0054s0019s0002li0022">22</link>). Interestingly, DeMuri et al. (<link linkend="ch0054s0019s0002li0023">23</link>) found that the density of <emphasis>Streptococcus pneumoniae, H. influenzae</emphasis>, and <emphasis>Moraxella catarrhalis</emphasis> increased between 0.4 and 1 log<subscript>10</subscript> during a concomitant upper respiratory viral infection. However, during infection, a single clonal group predominated (<link linkend="ch0054s0019s0002li0023">23</link>). As a result of widespread use of HIB, the distribution of serotypes causing invasive infection has shifted. Recent reports suggest most invasive disease is attributed to NTHi and <emphasis>H. influenzae</emphasis> serotype f. Of further note, the incidence of invasive <emphasis>H. influenzae</emphasis> disease attributable to <emphasis>H. influenzae</emphasis> serotype a has increased from 0.02 per 100,000 to 0.14 per 100,000 between 2002 and 2015, with children and First Nation communities being most impacted in the United States and Canada (<link linkend="ch0054s0019s0002li0019">19</link>). Variation in the incidence of each serotype has been reported by the World Health Organization (<link linkend="ch0054s0019s0002li0024">24</link>). Despite the reduction in Hib carriage and the efficacy of the vaccine in preventing invasive infections, the prevalence of invasive <emphasis>H. influenzae</emphasis> and Hib continues to remain high among First Nation populations (<link linkend="ch0054s0019s0002li0024">24</link>). Additionally, an increase in the incidence of invasive <emphasis>H. influenzae</emphasis> infections has been observed in patients aged &gt;65 years (<link linkend="ch0054s0019s0002li0025">25</link>, <link linkend="ch0054s0019s0002li0026">26</link>). The incidence of NTHi in adults has been reported to be 0.39 per 100,000, with most disease being observed in patients with comorbidities such as chronic respiratory diseases and immunosuppression (<link linkend="ch0054s0019s0002li0024">24</link>). During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, secondary infection of coronavirus disease 2019 (COVID-19) patients with <emphasis>H. influenzae</emphasis> was reported (<link linkend="ch0054s0019s0002li0027">27</link>). A comprehensive review on the incidence of invasive <emphasis>H. influenzae</emphasis> has been provided by Slack et al. (<link linkend="ch0054s0019s0002li0024">24</link>).</para>
        <anchor id="ch0054s0001s0002a0003"/>
        <beginpage pagenum="730"/>
        <table id="ch0054s0001s0002t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0054s0001s0002a0004"/><link linkend="ch0054s0001s0001a0004">TABLE 1</link></phrase></emphasis> Differential characteristics of <emphasis>Haemophilus</emphasis> spp.<superscript><emphasis><anchor id="ch0054s0001s0002a0005"/><link linkend="ch0054s0001s0002a0011">a</link></emphasis></superscript>
</title>
          
          <tgroup cols="14">
            <tbody>
              <row>
                <entry><phrase role="center">Species</phrase>
                </entry>
                <entry><phrase role="center">Requirement for:</phrase>
                </entry>
                <entry><phrase role="center">Fermentation of:</phrase>
                </entry>
                <entry><phrase role="center">Production of:</phrase>
                </entry>
                <entry><phrase role="center">Hemolysis</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="center">X factor</phrase>
                </entry>
                <entry><phrase role="center">V factor</phrase>
                </entry>
                <entry><phrase role="center">Catalase</phrase>
                </entry>
                <entry><phrase role="center">Glucose</phrase>
                </entry>
                <entry><phrase role="center">Sucrose</phrase>
                </entry>
                <entry><phrase role="center">Lactose</phrase>
                </entry>
                <entry><phrase role="center">Xylose</phrase>
                </entry>
                <entry><phrase role="center">Mannose</phrase>
                </entry>
                <entry><phrase role="center">Indole</phrase>
                </entry>
                <entry><phrase role="center">Urease</phrase>
                </entry>
                <entry><phrase role="center">Ornithine decarboxylase</phrase>
                </entry>
                <entry><phrase role="center">β-Galactosidase</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>H. influenzae</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">v<superscript><emphasis><anchor id="ch0054s0001s0002a0006"/><link linkend="ch0054s0001s0002a0012">b</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">v<superscript><emphasis><link linkend="ch0054s0001s0002a0012">b</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">v<superscript><emphasis><link linkend="ch0054s0001s0002a0012">b</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>H. aegyptius</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+<superscript><emphasis><anchor id="ch0054s0001s0002a0007"/><link linkend="ch0054s0001s0002a0013">c</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>H. haemolyticus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">v</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">v</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>H. parainfluenzae</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">v</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">v<superscript><emphasis><link linkend="ch0054s0001s0002a0012">b</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">v<superscript><emphasis><link linkend="ch0054s0001s0002a0012">b</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">v<superscript><emphasis><link linkend="ch0054s0001s0002a0012">b</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">v</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>H. ducreyi</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">v</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−<superscript><emphasis><anchor id="ch0054s0001s0002a0008"/><link linkend="ch0054s0001s0002a0014">d</link></emphasis></superscript></phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>H. parahaemolyticus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">v</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">v</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>H. pittmaniae</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">w</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">uk</phrase>
                </entry>
                <entry><phrase role="center">uk</phrase>
                </entry>
                <entry><phrase role="center">uk</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>H. paraphrohaemolyticus</emphasis>
                    <superscript>
                      <emphasis>
                        <anchor id="ch0054s0001s0002a0009"/>
                        <link linkend="ch0054s0001s0002a0015">e</link>
                      </emphasis>
                    </superscript>
                  </phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">v</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>H. sputorum</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">uk</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">uk</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+<superscript><emphasis><anchor id="ch0054s0001s0002a0010"/><link linkend="ch0054s0001s0002a0016">f</link></emphasis></superscript></phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0054s0001s0002a0011"/><link linkend="ch0054s0001s0002a0005">a</link></emphasis></superscript>+, positive; −, negative; uk, unknown; v, variable reaction; w, weak reaction.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0054s0001s0002a0012"/><link linkend="ch0054s0001s0002a0006">b</link></emphasis></superscript>Indole, urease, and ornithine decarboxylase production are the basis for biotyping schemes with <emphasis>H. influenzae</emphasis> and <emphasis>H. parainfluenzae</emphasis> as depicted in <link linkend="ch0054s0001s0002a0019">Table 2</link>.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0054s0001s0002a0013"/><link linkend="ch0054s0001s0002a0007">c</link></emphasis></superscript>A delayed positive reaction occurs in &gt;90% of strains.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0054s0001s0002a0014"/><link linkend="ch0054s0001s0002a0008">d</link></emphasis></superscript>Delayed development of hemolysis occurs in 11 to 89% of strains.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0054s0001s0002a0015"/><link linkend="ch0054s0001s0002a0009">e</link></emphasis></superscript>Elevated concentrations of CO<subscript>2</subscript> of ≥10% enhance growth.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0054s0001s0002a0016"/><link linkend="ch0054s0001s0002a0010">f</link></emphasis></superscript>Beta-hemolysis is produced on horse and sheep blood agar; occasional strains fail to produce beta-hemolysis.</para>
        <figure id="ch0054s0001s0002f0001"><title><phrase role="figureLabel"><anchor id="ch0054s0001s0002a0017"/><link linkend="ch0054s0001s0001a0007">FIGURE 2</link></phrase> Electron micrographs depicting an encapsulated type b strain (left) and a nonencapsulated, nontypeable strain (right) of <emphasis>H. influenzae</emphasis>.</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0054f12.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <para id="ch0054s0001s0002p0003">The incubation period for<emphasis>H. influenzae</emphasis> is poorly understood. The presence of a concomitant or preceding viral infection can predispose previously healthy carriers to infection. In these instances, colonizing bacteria invade the inflamed or damaged mucosa and enter the bloodstream. The antiphagocytic nature of the Hib capsule and the absence of anticapsular antibody lead to bacterial proliferation. When the bacterial concentration exceeds a critical level, the bacteria can disseminate to various sites, including the meninges, subcutaneous tissue, joints, pleura, pericardia, and lungs. The presence of antibody, complement, and phagocytic cells determines the clearance of the bacteremia and can influence dissemination (<link linkend="ch0054s0019s0002li0028">28</link>).</para>
        <anchor id="ch0054s0001s0002a0018"/>
        <beginpage pagenum="731"/>
        <table id="ch0054s0001s0002t0002"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0054s0001s0002a0019"/><link linkend="ch0054s0001s0001a0008">TABLE 2</link></phrase></emphasis> Biotypes of <emphasis>H. influenzae</emphasis> and <emphasis>H. parainfluenzae</emphasis>
</title>
          
          <tgroup cols="5">
            <tbody>
              <row>
                <entry><phrase role="center">Species</phrase>
                </entry>
                <entry><phrase role="center">Biotype</phrase>
                </entry>
                <entry><phrase role="center">Production of:</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="center">Indole</phrase>
                </entry>
                <entry><phrase role="center">Urease</phrase>
                </entry>
                <entry><phrase role="center">Ornithine decarboxylase</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>H. influenzae</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">I</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">II</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">III</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">IV</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">V</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">VI</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">VII</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">VIII</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>H. parainfluenzae</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">I</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">II</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">III</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">IV</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">V</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">VI</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">VII</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
              <row>
                <entry/>
                <entry><phrase role="left">VIII</phrase>
                </entry>
                <entry><phrase role="center">+</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
                <entry><phrase role="center">−</phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para id="ch0054s0001s0002p0004">Host defenses include activation of the alternative and classical complement pathways and production of antibodies directed against the polyribosylribitol phosphate capsule of Hib. Antibody reactive against the Hib capsule plays a primary role in conferring immunity. Newborns have a low risk of infection because of the presence of maternal antibodies. Beginning at about 2 months of age, when maternal antibodies to the polyribosylribitol phosphate capsule begin to wane, infants are at high risk for developing invasive<emphasis>H. influenzae</emphasis> disease. In the absence of maternal antibodies, and even following natural infection, the anti-polyribosylribitol phosphate immune response of infants is diminished (<link linkend="ch0054s0019s0002li0028">28</link>). Therefore, infants are at risk for repeat infections because prior episodes of infection do not confer immunity. By the age of 5 years, most children have naturally acquired antibodies.</para>
      </sect2>
      <sect2 id="ch0054s0001s0003">
        <title>CLINICAL SIGNIFICANCE</title>
        <anchor id="ch0054s0001s0003a0001"/>
        <anchor id="ch0054s0001s0003a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0054s0002">
      <title>H. influenzae</title>
      <anchor id="ch0054s0002a0001"/>
      <anchor id="ch0054s0002a0002"/>
      <para id="ch0054s0002p0001">Isolates of<emphasis>H. influenzae</emphasis> constitute a diverse group of organisms that cause a broad range of human diseases. To better group isolates of <emphasis>H. influenzae</emphasis>, Doern and Chapin demonstrated that strains can be grouped into eight biotypes based on their reactions to indole, urease, and ornithine decarboxylase (<link linkend="ch0054s0019s0002li0011">11</link>). Invasive infections caused by <emphasis>H. influenzae</emphasis>, such as meningitis, epiglottitis, orbital cellulitis, and bacteremia, are usually caused by capsular type a and b strains and generally fall within biotypes I and II of this species (<link linkend="ch0054s0019s0002li0029">29</link>). Life-threatening <emphasis>Haemophilus</emphasis> infections, however, have fortunately become exceedingly uncommon in developed countries since development and introduction of the pediatric HIB vaccine (<link linkend="ch0054s0019s0002li0030">30</link>–<link linkend="ch0054s0019s0002li0032">32</link>). When infections caused by Hib occur today, it is usually in the setting of an unvaccinated child, although they may also arise in both children and adults following head trauma or cerebrospinal fluid (CSF) leak or following a neurosurgical procedure. Biotype IV strains, at least in the pre-HIB vaccine era, were often found to cause systemic infections in neonates as well as aggressive infections of the genital tract in postpartum women (<link linkend="ch0054s0019s0002li0033">33</link>, <link linkend="ch0054s0019s0002li0034">34</link>).</para>
      <para id="ch0054s0002p0002">The vast majority of<emphasis>H. influenzae</emphasis> infections today are caused by NTHi (<link linkend="ch0054s0019s0002li0010">10</link>, <link linkend="ch0054s0019s0002li0021">21</link>). This organism is an important cause of acute conjunctivitis, acute otitis media, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, and pneumonia (<link linkend="ch0054s0019s0002li0018">18</link>). The organism gains access to the site of infection by direct contiguous spread from its reservoir in the URT. Spread via respiratory secretions, usually on the hands of patients, NTHi can also lead to conjunctival infection. Antecedent viral infections with resultant inflammation of the eustachian tubes and sinus ostia predispose patients to infection of the middle ear cavity and maxillary sinuses, respectively, by compromising egress from and ingress to these closed spaces (<link linkend="ch0054s0019s0002li0028">28</link>). Establishment of infection in the lungs is facilitated by any condition that diminishes mucociliary clearance of organisms from the respiratory tree (<link linkend="ch0054s0019s0002li0017">17</link>, <link linkend="ch0054s0019s0002li0035">35</link>, <link linkend="ch0054s0019s0002li0036">36</link>). Examples include smoking, chronic obstructive pulmonary disease, viral infection, recurrent bacterial infection, and physiological alterations, such as those that occur in individuals with cystic fibrosis (<link linkend="ch0054s0019s0002li0017">17</link>, <link linkend="ch0054s0019s0002li0035">35</link>, <link linkend="ch0054s0019s0002li0036">36</link>). Persons at risk for systemic NTHi infection, particularly the elderly, also include those with functional or anatomic asplenism, sickle cell disease, complement deficiencies, Hodgkin’s lymphoma, congenital or acquired hypogammaglobulinemia, and T-cell immunodeficiency states (e.g., HIV infection).</para>
    </sect1>
    <sect1 id="ch0054s0003">
      <title>H. ducreyi</title>
      <anchor id="ch0054s0003a0001"/>
      <anchor id="ch0054s0003a0002"/>
      <para id="ch0054s0003p0001">Chancroid is a sexually transmitted disease caused by<emphasis>H. ducreyi</emphasis> usually characterized by development of a single painful genital ulcer, with associated inguinal lymphadenopathy occurring 2 to 7 days following exposure (<link linkend="ch0054s0019s0002li0037">37</link>–<link linkend="ch0054s0019s0002li0039">39</link>). Keratinocytes are likely the first cell type encountered by <emphasis>H. ducreyi</emphasis> upon infection of human skin; thus, the interaction between <emphasis>H. ducreyi</emphasis> and keratinocytes is likely important in establishing infection (<link linkend="ch0054s0019s0002li0040">40</link>). Chancroid occurs most often in developing countries, including much of Asia, Africa, and Latin America. Epidemics of disease are associated with low socioeconomic status, poor hygiene, commercial sex work, and drug abuse. Recent studies on regions of the South Pacific where yaws (chronic skin infection caused by <emphasis>Treponema pallidum</emphasis> subsp. <emphasis>pertenue</emphasis>; see <ulink url="ch0079#ch0079s0001">chapter 62</ulink>) is endemic demonstrate an increase in the incidence of <emphasis>H. ducreyi</emphasis> infection when applying PCR-based diagnostic tools to patients with skin ulcers. Mitjà et al. (<link linkend="ch0054s0019s0002li0041">41</link>) reported that when <emphasis>H. ducreyi</emphasis> PCR was used for patients with a clinical diagnosis of yaws, 60% of patients were actually infected with <emphasis>H. ducreyi.</emphasis> After 1987, reported cases of chancroid in the United States declined steadily until 2001. Since then, the number of cases reported has fluctuated from 17 to 55 cases annually. In 2015, only 11 cases were reported to the CDC, with 7 states reporting at least 1 case (<link linkend="ch0054s0019s0002li0042">42</link>). Because of difficulties in establishing an etiologic diagnosis of <emphasis>H. ducreyi</emphasis> infection and limited resources in many countries of endemicity, the true incidence of chancroid is unknown. The incidence of <emphasis>H. ducreyi</emphasis> in the United States and other industrialized countries also remains unknown due to poor diagnostic techniques and underreporting, likely making chancroid a more important cause of genital ulcers than currently reported.</para>
    </sect1>
    <sect1 id="ch0054s0004">
      <title>Other Haemophilus spp.</title>
      <anchor id="ch0054s0004a0001"/>
      <anchor id="ch0054s0004a0002"/>
      <para id="ch0054s0004p0001"><emphasis>H. parainfluenzae</emphasis> remains the predominant species colonizing the URT, accounting for 75% of the <emphasis>Haemophilus</emphasis> microbiota in the oral cavity and pharynx. Interestingly, <emphasis>H. parainfluenzae</emphasis> does not routinely colonize the nasal cavity. <emphasis>H. parainfluenzae</emphasis> is thought to account for at least some cases of acute otitis media, acute sinusitis, and acute bacterial exacerbation of chronic bronchitis, although its role in these diseases is often inconclusive. It is identified infrequently as a cause of subacute bacterial endocarditis, and it is the H in the HACEK group (the other organisms being <emphasis>Aggregatibacter</emphasis> spp., <emphasis>Cardiobacterium</emphasis> spp., <emphasis>Eikenella corrodens</emphasis>, and <emphasis>Kingella</emphasis> spp.).</para>
      <para id="ch0054s0004p0002"><emphasis>H. aegyptius</emphasis>, a distinct species of <emphasis>Haemophilus</emphasis> that closely resembles biotype III strains of <emphasis>H. influenzae</emphasis> and that has been referred to as the Koch-Weeks bacillus, is a cause of acute purulent conjunctivitis (<link linkend="ch0054s0019s0002li0043">43</link>). This disease occurs most often in younger children, especially those having extensive contact with other children in closed settings, such as day care centers and school classrooms. It is characterized by rapid onset of conjunctival inflammation, visual disturbance, ocular pain, and pruritus, often involves both eyes, and is highly transmissible.</para>
      <para id="ch0054s0004p0003">Brazilian purpuric fever, a condition that occurs most often in South America, is characterized by rapid onset of high fever, hypotension, diffuse cutaneous hemorrhages, and abrupt vascular compromise (<link linkend="ch0054s0019s0002li0044">44</link>). The causative agent is often mistaken to be <emphasis>H. aegyptius</emphasis> but is instead classified in biogroup III of <emphasis>H. influenzae</emphasis> (<link linkend="ch0054s0019s0002li0044">44</link>, <link linkend="ch0054s0019s0002li0045">45</link>). These strains are characterized by the inability to ferment <phrase role="small">D</phrase>-xylose, a particular pattern of their housekeeping genes, a distinct rRNA restriction pattern, and resistance to serum bactericidal activity, making them unique among known <emphasis>H. influenzae</emphasis> biogroups (<link linkend="ch0054s0019s0002li0006">6</link>).</para>
      <anchor id="ch0054s0004a0003"/>
      <beginpage pagenum="732"/>
      <para id="ch0054s0004p0004">Other<emphasis>Haemophilus</emphasis> spp. have only rarely been implicated as causes of infection in humans, although lower respiratory tract infection, sinusitis, conjunctivitis, bacteremia, meningitis, wound infections, peritonitis, arthritis, osteomyelitis, and brain abscess have been documented in individual case reports or small case series (<link linkend="ch0054s0019s0002li0008">8</link>, <link linkend="ch0054s0019s0002li0046">46</link>).</para>
      <sect2 id="ch0054s0004s0001">
        <title>COLLECTION, TRANSPORT, AND STORAGE OF SPECIMENS</title>
        <anchor id="ch0054s0004s0001a0001"/>
        <anchor id="ch0054s0004s0001a0002"/>
        <para id="ch0054s0004s0001p0001">Collection of specimens for the diagnosis of<emphasis>Haemophilus</emphasis> infections is predicated on the nature of the infection being evaluated. Details of specimen collection and transport can be found in <ulink url="ch0035#ch0035s0001">chapter 19</ulink> of this <emphasis>Manual.</emphasis> For patients suspected of having meningitis, blood and CSF cultures should be performed. Middle ear fluid obtained by tympanocentesis is the specimen of choice for patients with otitis media; however, in patients with perforated tympanic membranes and otorrhea, an aseptically collected aspirate of middle ear fluid from the external auditory canal is also satisfactory. In cases of maxillary sinusitis, direct sinus aspirates or middle meatal swab specimens collected under endoscopic guidance should be obtained. Conjunctival swab specimens are required in the evaluation of patients thought to have <emphasis>Haemophilus</emphasis> conjunctivitis. In patients suspected of having bronchopulmonary infections due to <emphasis>Haemophilus</emphasis> spp., specimens representative of lower respiratory tract secretions should be obtained in such a way as to avoid contamination with oropharyngeal commensal microbiota. This means that collection of optimal specimens, such as bronchoalveolar lavage or bronchial washing (less preferable), should be performed to provide optimum specificity when evaluating patients suspected of having <emphasis>Haemophilus</emphasis> bronchopulmonary infections. While collection of sputum and tracheal aspirates is less invasive, distinguishing between pathogens and oral microbiota can be nearly impossible by this means. When bacterial pneumonia is suspected, blood cultures may also be obtained. Importantly, with one exception, nasal, nasopharyngeal, and nasal swab specimens are of no value in evaluating patients suspected of having <emphasis>Haemophilus</emphasis> infections at any of these respiratory tract sites. The one possible exception is cystic fibrosis patients experiencing an exacerbation. In this setting, an induced deep-cough specimen collected on a swab inserted into the posterior pharynx may be clinically useful (<link linkend="ch0054s0019s0002li0047">47</link>). In patients suspected of having <emphasis>Haemophilus</emphasis> infections in normally sterile sites, such as the pleural space, synovium, pericardium, or peritoneum, fluid aspirated aseptically from the site of involvement is the specimen of choice. Concomitant blood cultures should be performed.</para>
        <para id="ch0054s0004s0001p0002">Finally, specimens for culture of<emphasis>H. ducreyi</emphasis> should be collected from the margins of genital lesions with a saline- or broth-moistened swab. The swab should be immediately transported to the laboratory and plated without delay to avoid loss of organism viability. It is imperative that health care providers inform the laboratory of the clinical suspicion of chancroid so that appropriate media for culture of <emphasis>H. ducreyi</emphasis> can be employed. If extended transport is required, swab specimens should be plated directly at the time of collection in the patient care area, or the specimen swab should be placed in transport medium containing hemin (<link linkend="ch0054s0019s0002li0048">48</link>). It has been demonstrated that when refrigerated (4°C), Amies transport medium can maintain the viability of <emphasis>H. ducreyi</emphasis> for up to 3 days. Alternatively, specially formulated thioglycolate-hemin-based medium containing albumin and glutamine can be used to preserve organism viability for transport taking &gt;3 days (<link linkend="ch0054s0019s0002li0038">38</link>, <link linkend="ch0054s0019s0002li0049">49</link>). Studies evaluating the viability of <emphasis>H. ducreyi</emphasis> using flocked swabs and liquid Amies transport medium are limited, and additional studies are needed. While optimal cultivation of <emphasis>H. ducreyi</emphasis> is based on collection of ulcer materials, lymph node aspirates, pus, and aspirates from buboes can also be submitted for culture, albeit with less sensitivity than ulcer material. When cultivating <emphasis>H. ducreyi</emphasis> from these specimens, laboratories should consider allowing clinicians to directly plate specimens to maintain optimal recovery. Specimens for <emphasis>H. ducreyi</emphasis> nucleic acid amplification tests (NAATs) should be collected using standard collection techniques for nucleic acid amplification from genital specimens, although large-scale studies evaluating specific transport media have not been conducted.</para>
        <para id="ch0054s0004s0001p0003">Long-term storage of<emphasis>Haemophilus</emphasis> spp. is usually accomplished by lyophilization or freezing of isolates at −60 to −80°C in tryptic soy broth with &gt;10% glycerol or on porous beads (Pro-Lab Diagnostics, Round Rock, TX).</para>
      </sect2>
      <sect2 id="ch0054s0004s0002">
        <title>DIRECT EXAMINATION</title>
        <anchor id="ch0054s0004s0002a0001"/>
        <anchor id="ch0054s0004s0002a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0054s0005">
      <title>Microscopy</title>
      <anchor id="ch0054s0005a0001"/>
      <anchor id="ch0054s0005a0002"/>
      <para id="ch0054s0005p0001">On Gram stain,<emphasis>Haemophilus</emphasis> spp. appear as small, pleomorphic, Gram-negative coccobacilli with coccoid, coccobacillary, rod-shaped, or filamentous forms (<anchor id="ch0054s0005a0003"/><link linkend="ch0054s0005a0005">Fig. 3</link>). Because of the pleomorphism of <emphasis>Haemophilus</emphasis> spp., careful interpretation of Gram stain smears must be undertaken to avoid confusion with other Gram-negative bacteria, such as <emphasis>Neisseria meningitidis, Brucella</emphasis> spp., or <emphasis>Francisella</emphasis> spp. Underdecolorization of Gram stains may erroneously suggest the presence of <emphasis>S. pneumoniae, Listeria monocytogenes</emphasis>, or <emphasis>Streptococcus agalactiae</emphasis>.</para>
      <para id="ch0054s0005p0002">Gram stain smears of CSF should be prepared and examined and positive results reported within 1 h of receipt of the specimen in the laboratory directly to the health care provider who requested the test. With nonturbid specimens, following centrifugation in a cytocentrifuge, a concentrated smear should be prepared. A Gram stain should be performed immediately and examined for the presence of polymorphonuclear leukocytes and bacteria morphologically compatible with<emphasis>Haemophilus</emphasis> spp. In rare cases, CSF Gram stains may reveal many polymorphonuclear leukocytes but no bacteria. When this occurs, it may be useful to prepare another cytospin smear and stain with acridine orange.</para>
      <anchor id="ch0054s0005a0004"/>
      <beginpage pagenum="733"/>
      <figure id="ch0054s0005f0001"><title><phrase role="figureLabel"><anchor id="ch0054s0005a0005"/><link linkend="ch0054s0005a0003">FIGURE 3</link></phrase> Gram stain of <emphasis>H. influenzae</emphasis> present in CSF.</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0054f13.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0054s0005p0003">The approach used for Gram staining of CSF should be applied to pleural, peritoneal, synovial, and pericardial fluid specimens (see<ulink url="ch0035#ch0035s0001">chapter 19</ulink>). Middle ear fluid specimens and sinus aspirate Gram stains should be prepared directly from the specimen without cytocentrifugation.</para>
      <para id="ch0054s0005p0004">Gram stains of lower respiratory tract secretions may be prepared directly from the specimen (e.g., expectorated sputa, endotracheal suction specimens, transbronchial biopsy specimens, bronchial brush biopsy specimens, and thoracotomy specimens) or following cytocentrifugation (e.g., bronchial washes and bronchoalveolar lavage fluid).</para>
      <para id="ch0054s0005p0005">Strands of small, Gram-negative bacilli arranged in a railroad track-like manner on a direct Gram stain are highly suggestive of<emphasis>H. ducreyi.</emphasis> However, Gram staining of genital specimens for <emphasis>H. ducreyi</emphasis> is controversial because most genital ulcers contain mixed bacterial microbiota, making Gram stain interpretation difficult. Furthermore, the positive yield of <emphasis>H. ducreyi</emphasis> in a Gram stain is low in comparison to that of culture or detection with a NAAT.</para>
    </sect1>
    <sect1 id="ch0054s0006">
      <title>Antigen Detection</title>
      <anchor id="ch0054s0006a0001"/>
      <anchor id="ch0054s0006a0002"/>
      <para id="ch0054s0006p0001">Commercial immunochemical techniques are available for the detection of<emphasis>S. pneumoniae, Streptococcus agalactiae, H. influenzae</emphasis>, and <emphasis>N. meningitidis</emphasis> directly from CSF and other body fluids. The available kits for <emphasis>H. influenzae</emphasis> specifically detect type b. While these techniques provide rapid identification of the pathogen, they lack sensitivity and specificity compared with Gram staining (<link linkend="ch0054s0019s0002li0050">50</link>). Thus, the use of <emphasis>H. influenzae</emphasis> antigen detection is of limited clinical value and is discouraged. However, in certain clinical contexts, such as in resource-constrained regions when the prevalence of disease is high and routine culture is unreliable, antigen-based detection methods may be useful.</para>
    </sect1>
    <sect1 id="ch0054s0007">
      <title>Molecular Techniques</title>
      <anchor id="ch0054s0007a0001"/>
      <anchor id="ch0054s0007a0002"/>
      <para id="ch0054s0007p0001">NAATs have been developed to detect<emphasis>H. influenzae</emphasis> directly in various clinical specimens, including CSF, plasma, serum, and whole blood (<link linkend="ch0054s0019s0002li0032">32</link>, <link linkend="ch0054s0019s0002li0051">51</link>). These techniques can be multiplexed to detect other common bacterial causes of specific infectious disease entities, such as meningitis. While publications cite variable detection sensitivities of these techniques, specificity is generally excellent (<link linkend="ch0054s0019s0002li0052">52</link>–<link linkend="ch0054s0019s0002li0054">54</link>).</para>
      <para id="ch0054s0007p0002">Studies have demonstrated that the diagnostic accuracy of chancroid based on clinical presentation and patient history ranges from 33 to 80% (<link linkend="ch0054s0019s0002li0055">55</link>) and that culture is ~75% sensitive (<link linkend="ch0054s0019s0002li0056">56</link>, <link linkend="ch0054s0019s0002li0057">57</link>), making it an ideal target for molecular techniques. Molecular strategies were developed to directly detect <emphasis>H. ducreyi</emphasis> from clinical specimens. Primers for these assays amplify sequences from either the <emphasis>H. ducreyi</emphasis> 16S rRNA gene, the <emphasis>rrs</emphasis> (16S)-<emphasis>rrl</emphasis> (23S) ribosomal intergenic spacer region, an anonymous fragment of cloned <emphasis>H. ducreyi</emphasis> DNA, or the <emphasis>groEL</emphasis> gene, which encodes the <emphasis>H. ducreyi</emphasis> heat shock protein (<link linkend="ch0054s0019s0002li0056">56</link>). The sensitivity of NAAT directly from clinical specimens varies among assays between 83 and 95% compared to culture or clinical diagnosis (<link linkend="ch0054s0019s0002li0056">56</link>, <link linkend="ch0054s0019s0002li0058">58</link>). Improved molecular methods may offer superior sensitivity for diagnosis of chancroid; they are clearly advantageous in areas where the organism is endemic, particularly where testing by culture is difficult or impossible.</para>
      <para id="ch0054s0007p0003">In addition to direct detection of<emphasis>H. ducreyi</emphasis> from clinical specimens, studies have also applied NAAT to direct detection of <emphasis>H. influenzae</emphasis> and <emphasis>H. parainfluenzae</emphasis> from clinical specimens. Kühn et al. (<link linkend="ch0054s0019s0002li0059">59</link>) evaluated three commercial NAATs for detection of infectious agents associated with infective endocarditis. This study demonstrated superior performance of NAAT compared with culture using both whole blood and valve tissue; the sensitivity of NAAT reached 85%, compared with 45% for culture from both whole blood and heart valve tissue. However, while this study resulted in high sensitivity for NAAT, the specificity was low (40%) due to culture-negative specimens, likely because of antimicrobial treatment of patients prior to collection of diagnostic specimens (<link linkend="ch0054s0019s0002li0059">59</link>). In a study of meningitis, Wu et al. (<link linkend="ch0054s0019s0002li0060">60</link>) demonstrated that the sensitivity of NAAT and Gram stain was less affected by the presence of antibiotics than culture and Gram stain for detection of <emphasis>H. influenzae, N. meningitidis</emphasis>, and <emphasis>S. pneumoniae.</emphasis> The study further demonstrated that the sensitivity of NAAT and Gram stain exceeded that of culture (95.7, 98.3, and 81.3% for <emphasis>H. influenzae, N. meningitidis</emphasis>, and <emphasis>S. pneumoniae</emphasis>, respectively) and resulted in identification of an additional 33 (of 451 total specimens) cases of meningitis that were culture negative (<link linkend="ch0054s0019s0002li0060">60</link>). Other studies have evaluated molecular methods to detect <emphasis>Haemophilus</emphasis> spp. from respiratory specimens (<link linkend="ch0054s0019s0002li0061">61</link>–<link linkend="ch0054s0019s0002li0063">63</link>), demonstrating sensitivity of up to 95%, compared to culture and/or serologic testing, not necessarily correlating with clinical disease.</para>
      <para id="ch0054s0007p0004">The BioFire FilmArray meningitis/encephalitis panel (bioMérieux, Marcy l’Etoile, France) has FDA clearance for direct detection of bacterial (<emphasis>n</emphasis> = 6), viral (<emphasis>n</emphasis> = 7), and fungal (<emphasis>n</emphasis> = 1) pathogens from ~200 μl of CSF specimen. Included on the panel is <emphasis>H. influenzae</emphasis>, and it can detect serotypes a to f and NTHi with a combination of two detection assays that report a single “<emphasis>H. influenzae</emphasis>” result. In four separate studies, <emphasis>H. influenzae</emphasis> was detected in a total of nine clinical specimens. Seven of these detections were culture confirmed, while the remaining two were confirmed by secondary methods (<link linkend="ch0054s0019s0002li0064">64</link>–<link linkend="ch0054s0019s0002li0067">67</link>). Liesman et al. tested a bank of previously characterized residual CSF specimens, including 40 <emphasis>H. influenzae</emphasis> positive specimens, and found that the positive and negative percent agreement for the FilmArray meningitis/encephalitis panel was 97.5% and 100%, respectively (<link linkend="ch0054s0019s0002li0068">68</link>). The BioFire joint infection panel (BioMérieux) received FDA-clearance for direct detection of bacterial (<emphasis>n</emphasis> = 29), and yeast (<emphasis>n</emphasis> = 2) pathogens along with antimicrobial resistance genes (<emphasis>n</emphasis> = 8) from 0.2 mL of synovial fluid. <emphasis>H. influenzae</emphasis> is included on this panel. While a few studies are published evaluating the BioFire joint infection panel, only the study by Schoenmakers et al. (<link linkend="ch0054s0019s0002li0069">69</link>) reported one <emphasis>H. influenzae</emphasis> detection. This (<link linkend="ch0054s0019s0002li0069">69</link>) and the other studies (<link linkend="ch0054s0019s0002li0070">70</link> and <link linkend="ch0054s0019s0002li0071">71</link>) did not note any false-positive results for <emphasis>H. influenzae</emphasis> with the BioFire joint infection panel, but more studies are needed to determine the utility of this test for <emphasis>H. influenzae</emphasis> detection. Recently, the BioFire FilmArray pneumonia panel (bioMérieux) received FDA clearance for direct detection of bacteria (<emphasis>n</emphasis> = 18), viruses (<emphasis>n</emphasis> = 8), and antimicrobial resistance genes (<emphasis>n</emphasis> = 7) from respiratory specimens (i.e., bronchoalveolar lavage-like [BAL] specimens, sputum, and endotracheal aspirates). For 15 of the bacterial targets, the panel can provide a semiquantitative abundance estimate from 10<superscript>4</superscript> to ≥10<superscript>7</superscript> genomic copies/mL. In a multicenter study by Murphy et al., wherein the authors compared 1,682 FilmArray pneumonia panels to reference quantitative cultures, the sensitivity and specificity for <emphasis>H. influenzae</emphasis> detection from BAL specimens were 100% and 91.4%, respectively, and those for sputum specimens were 88.9% and 88.9%, respectively (<link linkend="ch0054s0019s0002li0072">72</link>). For the 163 false-positive detections from BAL (<emphasis>n</emphasis> = 72) and sputum (<emphasis>n</emphasis> = 91) specimens, <emphasis>H. influenzae</emphasis> was identified at levels below the reference culture quantitative threshold (<emphasis>n</emphasis> = 11), in the standard-of-care testing (<emphasis>n</emphasis> = 3), or by an alternative molecular method (<emphasis>n</emphasis> = 149) (<link linkend="ch0054s0019s0002li0072">72</link>). The Unyvero lower respiratory tract (LRT) BAL application (OpGen, Rockville, MD) received FDA clearance for direct detection of bacteria (<emphasis>n</emphasis> = 19), <emphasis>Pneumocystis jirovecii</emphasis>, and antibiotic resistance markers (<emphasis>n</emphasis> = 10). Klein et al. (<link linkend="ch0054s0019s0002li0073">73</link>), in a multicenter study evaluation of the Unyvero LRT BAL application compared to culture, tested 1,016 prospectively collected and 392 archived BAL specimens (<link linkend="ch0054s0019s0002li0073">73</link>). For <emphasis>H. influenzae</emphasis>, they found an overall positive and negative percent agreement of 98.3% and 94.9%, respectively (<link linkend="ch0054s0019s0002li0073">73</link>). Secondary testing by an alternative PCR and sequencing confirmed 59 of the 69 Unyvero LRT BAL <emphasis>H. influenzae</emphasis> detections not identified by culture, while 9 false positives were other <emphasis>Haemophilus</emphasis> species or <emphasis>Aggregatibacter</emphasis> species (<link linkend="ch0054s0019s0002li0073">73</link>). For these multiplex respiratory panels, the exact significance of additional <emphasis>H. influenzae</emphasis> detections not detected by the reference or standard-of-care cultures warrants caution with interpretation of positive results.</para>
      <anchor id="ch0054s0007a0003"/>
      <beginpage pagenum="734"/>
      <sect2 id="ch0054s0007s0001">
        <title>ISOLATION PROCEDURES</title>
        <anchor id="ch0054s0007s0001a0001"/>
        <anchor id="ch0054s0007s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0054s0008">
      <title>Media</title>
      <anchor id="ch0054s0008a0001"/>
      <anchor id="ch0054s0008a0002"/>
      <para id="ch0054s0008p0001">Optimum recovery of<emphasis>Haemophilus</emphasis> spp. in culture requires enriched media that support the growth of these fastidious bacteria. Media must contain at least 10 μg/ml of free X and V factors. High concentrations of both the X and the V factors are found in whole blood, most sequestered within erythrocytes. X factor is protoporphyrin IX and can be derived from whole blood or added to bacteriological media using crystalline hemin; X factor is readily available in standard blood agar. V factor is composed of nicotinamide complexed as NAD or NADP and is also readily available in blood. However, nicotinamide is not readily bioavailable because of its intracellular location and the presence of NAD-glycohydrolase enzymes in blood. For growth of <emphasis>Haemophilus</emphasis> spp. on solid media, either crystalline hemin and NAD must be added to a final concentration of 10 μg/ml or the blood used in the medium must be heated such that the red cells lyse and release free X factor and V factor into the medium. The latter can be accomplished by adding blood to the basal medium as it cools to 80°C after being autoclaved. This is referred to as “chocolatizing” blood. For optimal growth of <emphasis>Haemophilus</emphasis> spp., a concentration of 5% chocolatized sheep blood should be employed (<link linkend="ch0054s0019s0002li0001">1</link>).</para>
      <para id="ch0054s0008p0002">The optimum growth of<emphasis>Haemophilus</emphasis> spp., especially of more fastidious species, such as <emphasis>H. ducreyi</emphasis> and <emphasis>H. aegyptius</emphasis>, requires, in addition to the X and V factors, supplementation of media with various other growth factors. Two commercially available supplements that supply these growth factor requirements are IsoVitaleX (BD) and Vitox (Thermo Fisher). These growth factors contain glucose, cystine, glutamine, adenine, thiamine, vitamin B<subscript>12</subscript>, guanine, iron, and aminobenzoic acid and provide adequate supplementation for the growth of <emphasis>H. ducreyi</emphasis> and <emphasis>H.</emphasis> <emphasis>aegyptius</emphasis>.</para>
      <para id="ch0054s0008p0003">Enriched chocolate agar containing 5% lysed sheep red blood cells and supplemented with 1% IsoVitaleX or 1% Vitox is one general-purpose medium that is commonly used in clinical laboratories to propagate<emphasis>Haemophilus</emphasis> spp. (<anchor id="ch0054s0008a0003"/><link linkend="ch0054s0008a0005">Fig. 4</link>). Another medium that reliably supports the growth of <emphasis>Haemophilus</emphasis> spp. is Levinthal’s medium (<link linkend="ch0054s0019s0002li0074">74</link>). Because of its transparency, Levinthal’s medium offers the added benefit of permitting detection of colony iridescence, a property that is frequently associated with encapsulation (<anchor id="ch0054s0008a0004"/><link linkend="ch0054s0008a0006">Fig. 5</link>) (<link linkend="ch0054s0019s0002li0075">75</link>, <link linkend="ch0054s0019s0002li0076">76</link>). One investigation found that a medium consisting of GC agar base, 5% heated sheep red blood cells, and 1% yeast autolysate provided the best growth for all <emphasis>Haemophilus</emphasis> spp. other than <emphasis>H. ducreyi</emphasis> (<link linkend="ch0054s0019s0002li0077">77</link>).</para>
      <figure id="ch0054s0008f0001"><title><phrase role="figureLabel"><anchor id="ch0054s0008a0005"/><link linkend="ch0054s0008a0003">FIGURE 4</link></phrase> Colony morphologies of type b encapsulated (left) and nonencapsulated (right) strains of <emphasis>H. influenzae</emphasis> propagated on enriched chocolate agar.</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0054f14.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <figure id="ch0054s0008f0002"><title><phrase role="figureLabel"><anchor id="ch0054s0008a0006"/><link linkend="ch0054s0008a0004">FIGURE 5</link></phrase> Colony morphologies of type b encapsulated (left and right) and nonencapsulated (center) strains of <emphasis>H. influenzae</emphasis> propagated on Levinthal’s agar. Note the conspicuous iridescence apparent with the encapsulated strain.</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0054f15.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0054s0008p0004">A significant challenge in the recovery of<emphasis>Haemophilus</emphasis> spp. from respiratory specimens is bacterial overgrowth due to the presence of other less fastidious commensal bacteria. Supplementation of media with some combination of bacitracin, vancomycin, and/or clindamycin inhibits overgrowth with commensals, permitting the recovery of <emphasis>Haemophilus</emphasis> spp. (<link linkend="ch0054s0019s0002li0078">78</link>). Use of such selective media is particularly relevant to the recovery of <emphasis>Haemophilus</emphasis> spp. from respiratory tract specimens from patients with cystic fibrosis, acute exacerbation of chronic bronchitis, conjunctivitis, and epiglottitis (<anchor id="ch0054s0008a0007"/><link linkend="ch0054s0008a0008">Fig. 6</link>) (<link linkend="ch0054s0019s0002li0079">79</link>). Several versions of selective <emphasis>Haemophilus</emphasis> media are available commercially, including <emphasis>Haemophilus</emphasis> isolation agar (Thermo Fisher) and <emphasis>Haemophilus</emphasis> isolation agar with bacitracin (BD). These media contain beef heart infusion agar with casein peptone to supply nutritional requirements, combined with horse blood to supply the X and V factors and distinguish hemolytic species of <emphasis>Haemophilus</emphasis> from those that are not hemolytic. Bacitracin is added to inhibit members of the normal microbiota, including <emphasis>Neisseria</emphasis> spp.</para>
      <figure id="ch0054s0008f0003"><title><phrase role="figureLabel"><anchor id="ch0054s0008a0008"/><link linkend="ch0054s0008a0007">FIGURE 6</link></phrase> Colony growth from an expectorated-sputum specimen containing <emphasis>H. influenzae</emphasis> from a patient with cystic fibrosis propagated on enriched chocolate agar (left) and enriched chocolate agar containing bacitracin, clindamycin, and vancomycin (right).</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0054f16.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0054s0008p0005">The use of selective media is also helpful in recovering<emphasis>H. ducreyi</emphasis> from genital tract specimens (<link linkend="ch0054s0019s0002li0049">49</link>). Selective media may include any of the following: GC agar base with 1% IsoVitaleX, 5% fetal bovine serum, 1% hemoglobin, and 3 μg vancomycin; GC agar base with 5% Fildes enrichment, 5% horse blood, and 3 μg vancomycin; 5% fresh rabbit blood agar with 3 μg vancomycin; or Mueller-Hinton agar with 5% chocolatized horse blood, 1% IsoVitaleX, and 3 μg vancomycin (<link linkend="ch0054s0019s0002li0049">49</link>). Preferably, two different selective media are employed to ensure optimal sensitivity (<link linkend="ch0054s0019s0002li0049">49</link>).</para>
      <anchor id="ch0054s0008a0009"/>
      <beginpage pagenum="735"/>
      <para id="ch0054s0008p0006">Growth of<emphasis>Haemophilus</emphasis> spp. may also be achieved on 5% sheep blood agar by use of the microsatellite phenomenon, although it is not recommended for routine clinical testing. With the microsatellite test, a single streak line of hemolysin-producing <emphasis>Staphylococcus aureus</emphasis> is placed on an agar surface previously inoculated with a specimen suspected of containing <emphasis>Haemophilus</emphasis> spp. The hemolysin produced by the <emphasis>Staphylococcus</emphasis> species lyses erythrocytes immediately adjacent to the streak line in the medium, releasing sufficient concentrations of X factor (hemin) and V factor (NAD) into the medium to supply the growth factor requirements of <emphasis>Haemophilus</emphasis> spp. <emphasis>S. aureus</emphasis> also secretes NAD into the medium in proximity to the streak line. Colonies of <emphasis>Haemophilus</emphasis> thus appear in a narrow zone adjacent to the staphylococcal streak. This is referred to as “satelliting” growth (<anchor id="ch0054s0008a0010"/><link linkend="ch0054s0008a0011">Fig. 7</link>). Organisms other than <emphasis>S. aureus</emphasis> may also produce the satellite phenomenon with <emphasis>Haemophilus</emphasis>, e.g., other <emphasis>Staphylococcus</emphasis> species, enterococci, and yeast.</para>
      <figure id="ch0054s0008f0004"><title><phrase role="figureLabel"><anchor id="ch0054s0008a0011"/><link linkend="ch0054s0008a0010">FIGURE 7</link></phrase> Satellite phenomenon observed when <emphasis>H. influenzae</emphasis> is propagated next to a streak of <emphasis>S. aureus</emphasis> on a 5% sheep blood agar plate.</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0054f17.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0054s0008p0007">Although<emphasis>Haemophilus</emphasis> spp. are not a common cause of bacteremia, special techniques are unnecessary for their recovery from blood specimens with modern, continuously monitoring blood culture systems (<link linkend="ch0054s0019s0002li0008">8</link>, <link linkend="ch0054s0019s0002li0080">80</link>). The broth medium used in such systems supports growth of <emphasis>Haemophilus</emphasis> spp. because the blood specimen itself supplies adequate concentrations of both X and V factors when erythrocytes present in the specimen lyse as they come into contact with the blood culture broth. However, the common practice of using such systems for culture of normally sterile body fluids, e.g., synovial, peritoneal, pericardial, and pleural fluid, may be problematic insofar as these specimens may not contain sufficient blood to supply the necessary levels of the X and V factors to support the growth of <emphasis>Haemophilus</emphasis> spp. In situations where a <emphasis>Haemophilus</emphasis> sp. is strongly suspected in such specimens, blood culture bottles may be supplemented with at least 10 μg of both sterile hemin and NAD/ml prior to inoculation with clinical specimens. The use of commercial supplements such as Fildes enrichment (BD) can be considered to aid in the propagation of <emphasis>Haemophilus</emphasis> spp., although studies demonstrate variable utility (<link linkend="ch0054s0019s0002li0080">80</link>, <link linkend="ch0054s0019s0002li0081">81</link>).</para>
      <para id="ch0054s0008p0008">Following inoculation, solid media should be incubated at 35 to 37°C in a moist atmosphere and in the presence of 5 to 7% CO<subscript>2.</subscript> Under these conditions, most <emphasis>Haemophilus</emphasis> spp. grow within 24 to 48 h. When specimens for <emphasis>H. ducreyi</emphasis> and <emphasis>H. aegyptius</emphasis> are cultured, incubation may be necessary for up to 5 days to allow sufficient time for the growth of these fastidious organisms. Further, when attempting to propagate <emphasis>H. ducreyi</emphasis>, plates should be incubated at slightly lower temperatures, i.e., 30 to 33°C in 5% CO<subscript>2</subscript> in a high-moisture environment. Use of lower incubation temperatures will improve the recovery of <emphasis>H. ducreyi</emphasis> in comparison to incubation temperatures of 35 to 37°C.</para>
    </sect1>
    <sect1 id="ch0054s0009">
      <title>Colony Appearance</title>
      <anchor id="ch0054s0009a0001"/>
      <anchor id="ch0054s0009a0002"/>
      <para id="ch0054s0009p0001">Colonies of<emphasis>Haemophilus</emphasis> spp. on suitable solid media, in general, are nonpigmented or slightly yellow and flat to convex and have a diameter of 0.5 to 2 mm after 48 h of incubation. Certain species of <emphasis>Haemophilus</emphasis> produce β-hemolysis (<link linkend="ch0054s0001s0002a0004">Table 1</link>).</para>
      <para id="ch0054s0009p0002">Colonies of<emphasis>H. influenzae</emphasis> on chocolate agar are smooth, low, convex, grayish, and translucent. Encapsulated strains often have a mucoid appearance, while nonencapsulated strains produce smaller, buff colonies (<link linkend="ch0054s0008a0005">Fig. 4</link>). Most strains of <emphasis>H. influenzae</emphasis> produce indole, emitting a strong amine-like odor. Non-indole-producing strains emit a “mousy” odor. Colonies are 1 to 2 mm in diameter and often grow within 24 h. Colonies grown on clear media, such as Levinthal’s agar, demonstrate iridescence under obliquely transmitted light (<link linkend="ch0054s0019s0002li0075">75</link>, <link linkend="ch0054s0019s0002li0076">76</link>). Iridescence is most conspicuous with young colonies and disappears with age. Iridescent colors may include yellow, red, green, or blue. Iridescence is more apparent with capsular type b strains; nonencapsulated strains typically demonstrate a blue-green color (<link linkend="ch0054s0008a0006">Fig. 5</link>).</para>
      <para id="ch0054s0009p0003">Colonies of<emphasis>H. aegyptius</emphasis> reach a colony size of only approximately 0.5 mm after 48 h of growth. Colonies are low, convex, and translucent, with a smooth, entire surface. On semisolid agar medium (which contains ~0.4% agar, compared with 1.5% for solid medium), “comet-like” colonies are produced (<link linkend="ch0054s0019s0002li0006">6</link>, <link linkend="ch0054s0019s0002li0043">43</link>).</para>
      <para id="ch0054s0009p0004">Colonies of<emphasis>H. parainfluenzae</emphasis> are typically off-white to yellow and, like those of <emphasis>H. influenzae</emphasis>, 1 to 2 mm in diameter after 24 h of growth. The colony appearance is extremely varied, i.e., flat and smooth, granular with serrated edges or heaped up and wrinkled. Colonies exhibiting the latter morphology may be slid intact across the surface of the agar. The colony morphology of <emphasis>H. parainfluenzae</emphasis> may change as the colonies age.</para>
      <anchor id="ch0054s0009a0003"/>
      <beginpage pagenum="736"/>
      <para id="ch0054s0009p0005">Colonies of<emphasis>H. haemolyticus</emphasis> are translucent, smooth, and convex and do not form satellites around <emphasis>S. aureus.</emphasis> Colonies usually achieve a diameter of 0.5 to 1.5 mm after 24 h, with a clear zone of β-hemolysis surrounding each colony when the organism is grown on blood agar; <emphasis>H. haemolyticus</emphasis> can lose its ability to cause hemolysis following serial subculture on bacteriological media. Growth properties and colony morphology of <emphasis>H. parahaemolyticus</emphasis> and <emphasis>H. paraphrohaemolyticus</emphasis> are similar to those of <emphasis>H. hae</emphasis><emphasis>molyticus</emphasis>.</para>
      <para id="ch0054s0009p0006"><emphasis>H. ducreyi</emphasis> grows poorly, regardless of the medium used, and frequently 3 to 5 days will pass before growth appears. Colonies growing on chocolate agar are small, flat, gray, and smooth. Larger colonies may be interspersed among small colonies but have the same morphology. Growth on blood agar is poor, with a slight β-hemolysis surrounding the colonies. As with <emphasis>H. parainfluenzae</emphasis>, older colonies of <emphasis>H. ducreyi</emphasis> are cohesive and can be slid across the agar.</para>
      <sect2 id="ch0054s0009s0001">
        <title>IDENTIFICATION</title>
        <anchor id="ch0054s0009s0001a0001"/>
        <anchor id="ch0054s0009s0001a0002"/>
        <para id="ch0054s0009s0001p0001">The identification and differentiation of<emphasis>Haemophilus</emphasis> spp. may be achieved through determination of X and V factor requirements for growth, performance of the porphyrin test, assessment of hemolysis (from blood agar for species that will grow on blood agar), determination of carbohydrate fermentation patterns, and production of indole, ornithine decarboxylase, urease, catalase, and β-galactosidase (<link linkend="ch0054s0001s0002a0004">Table 1</link>). The pattern of X and V growth factor requirements and the porphyrin test provide sufficient information for presumptive species identification of selected <emphasis>Haemophilus</emphasis> spp. Definitive species identification, however, requires assessment of the other phenotypic characteristics listed above (<link linkend="ch0054s0001s0002a0004">Table 1</link>). Alternatively, sequencing of the 16S rRNA gene and matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) provide definitive identification of these organisms.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0054s0010">
      <title>X and V Factor Growth Requirements</title>
      <anchor id="ch0054s0010a0001"/>
      <anchor id="ch0054s0010a0002"/>
      <para id="ch0054s0010p0001">X and V factor requirements for the growth of<emphasis>Haemophilus</emphasis> spp. may be determined by swab inoculation of a suspension of test organism equivalent in turbidity to a 0.5 McFarland standard across the entire surface of a 100-mm petri dish containing tryptic soy agar. Filter paper disks or strips impregnated with X factor, V factor, and X and V factors are then placed on the agar surface, and the plate is incubated for 20 to 24 h at 35°C in an atmosphere of 5 to 7% CO<subscript>2.</subscript> The pattern of satellite growth around individual disks or strips, in the absence of growth elsewhere on the plate, is used to define the growth factor requirements of the test strain (<anchor id="ch0054s0010a0003"/><link linkend="ch0054s0010a0004">Fig. 8</link>). Tryptic soy agar is the preferred medium for use when the X and V growth factor requirements for <emphasis>Haemophilus</emphasis> spp. are determined, as other media may yield erroneous results (<link linkend="ch0054s0019s0002li0082">82</link>, <link linkend="ch0054s0019s0002li0083">83</link>). Alternatively, triplates (<emphasis>Haemophilus</emphasis> ID II; Thermo Fisher) and quadplates (<emphasis>Haemophilus</emphasis> ID Quad; Thermo Fisher) can be used to assess X and V growth factor requirements. When performing X and V factor studies, care should be taken to avoid carrying X factor along with the inoculum. This can result in erroneous identification of <emphasis>H. influenzae</emphasis> as <emphasis>H. parainfluenzae</emphasis>.</para>
      <para id="ch0054s0010p0002">All X factor-requiring species of<emphasis>Haemophilus</emphasis>, most notably <emphasis>H. influenzae</emphasis>, lack the enzymes necessary to convert δ-aminolevulinic acid (ALA) into protoporphyrin, a metabolic intermediate in the biosynthesis of X factor (<link linkend="ch0054s0019s0002li0084">84</link>). Thus, they require that X factor be supplied exogenously to support growth. By taking advantage of this observation, a rapid test, known as the porphyrin or ALA test, can be performed to quickly determine if a test organism requires X factor for growth (<link linkend="ch0054s0019s0002li0085">85</link>). When positive, the porphyrin test indicates that the test organism is X factor independent; when negative, the porphyrin test indicates that the organism requires X factor. Since most X factor-requiring <emphasis>Haemophilus</emphasis> spp. recovered in the clinical laboratory are <emphasis>H. influenzae</emphasis>, when the porphyrin test is performed with a clinical isolate and found to be negative, it can be inferred with a high likelihood that the organism is <emphasis>H. i</emphasis><emphasis>nfluenzae</emphasis>.</para>
      <figure id="ch0054s0010f0001"><title><phrase role="figureLabel"><anchor id="ch0054s0010a0004"/><link linkend="ch0054s0010a0003">FIGURE 8</link></phrase> Use of X and V factor disks and strips in determining the growth factor requirements of <emphasis>H. influenzae</emphasis> (disks on left) and <emphasis>H. parainfluenzae</emphasis> (disks on right).</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0054f18.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0054s0010p0003">The porphyrin test is performed using commercially available ALA disks or through preparation of liquid porphyrin medium (<link linkend="ch0054s0019s0002li0085">85</link>). To prepare liquid porphyrin medium, 2 mM ALA and 0.8 mM MgSO<subscript>4</subscript> in 0.1 M phosphate buffer (pH 6.9) are aliquoted in glass tubes with 0.5 ml of porphyrin medium in each tube. Tubes can be stored for several months at 4°C or for years at −20°C. Tubes are inoculated with a loopful of freshly grown bacteria and incubated for 4 h at 35°C in ambient air (<link linkend="ch0054s0019s0002li0001">1</link>). Following incubation, tubes are examined for brick-red fluorescence with a device, such as a Wood’s lamp, that emits a 360-nm long-wave UV light (<anchor id="ch0054s0010a0005"/><link linkend="ch0054s0011a0004">Fig. 9</link>). Tubes with questionable results may be reincubated for up to 24 h. Alternatively, Kovács reagent (0.5 ml) can be added to the liquid porphyrin medium, and the tube is shaken and observed for a red color in the lower water phase (<link linkend="ch0054s0019s0002li0001">1</link>). A negative-control tube lacking ALA should also be inoculated when the porphyrin test is performed to rule out false-positive reactions due to the presence of indole. The porphyrin test has been shown in several studies to outperform growth factor-based methods for differentiation of <emphasis>H. influenzae</emphasis> from non-<emphasis>H. influenzae</emphasis> species (<link linkend="ch0054s0019s0002li0086">86</link>).</para>
    </sect1>
    <sect1 id="ch0054s0011">
      <title>Conventional Biochemical Tests</title>
      <anchor id="ch0054s0011a0001"/>
      <anchor id="ch0054s0011a0002"/>
      <para id="ch0054s0011p0001">The list of biochemicals necessary for the differentiation of<emphasis>Haemophilus</emphasis> spp. is provided in <link linkend="ch0054s0001s0002a0004">Table 1</link>. Carbohydrate fermentation is determined in phenol red broth containing 1% carbohydrate supplemented with 10 μg/ml NAD and hemin. Following heavy inoculation, fermentation tubes are incubated at 35°C without CO<subscript>2</subscript> for up to 1 week and examined periodically for a red to yellow color, indicating a positive reaction. Usually, positive reactions become apparent within 24 h; however, <emphasis>H. aegyptius</emphasis> and <emphasis>A. segnis</emphasis> have been noted to demonstrate weak reactions following a 24-h incubation (<link linkend="ch0054s0019s0002li0001">1</link>).</para>
      <anchor id="ch0054s0011a0003"/>
      <beginpage pagenum="737"/>
      <figure id="ch0054s0011f0001"><title><phrase role="figureLabel"><anchor id="ch0054s0011a0004"/><link linkend="ch0054s0010a0005">FIGURE 9</link></phrase> Positive (top) and negative (bottom) porphyrin tests.</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0054f19.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0054s0011p0002">Indole production can be reliably determined with most strains of<emphasis>H. influenzae</emphasis> and <emphasis>H. parainfluenzae</emphasis> by using a spot indole test. However, reliable assessment of indole production by other <emphasis>Haemophilus</emphasis> spp. requires use of a solution of 0.1% <phrase role="small">L</phrase>-tryptophan in 0.067 M phosphate buffer at pH 6.8. Following inoculation, the suspension is incubated for 4 h at 35°C in ambient air, 0.5 ml of Kovács reagent is added to the tube, and the tube is shaken and examined for the appearance of red color in the upper portion of the tube as an indication of a positive reaction (<link linkend="ch0054s0019s0002li0001">1</link>, <link linkend="ch0054s0019s0002li0006">6</link>) (<anchor id="ch0054s0011a0005"/><link linkend="ch0054s0011a0006">Fig. 10</link>).</para>
      <para id="ch0054s0011p0003">Production of ornithine decarboxylase is determined using the ornithine decarboxylase test (see<ulink url="ch0036#ch0036s0001s0001">chapter 20</ulink>) or Moeller medium. A tube containing either medium is heavily inoculated, incubated for 4 to 24 h at 35°C in ambient air, and examined for purple coloration as an indication that the organism produces ornithine decarboxylase (<link linkend="ch0054s0019s0002li0001">1</link>, <link linkend="ch0054s0019s0002li0006">6</link>) (<link linkend="ch0054s0011a0006">Fig. 10</link>). Species of <emphasis>Haemophilus</emphasis> that are positive for ornithine decarboxylase include several biotypes of <emphasis>H. influenzae</emphasis> and <emphasis>H. parainfluenzae</emphasis>.</para>
      <figure id="ch0054s0011f0002"><title><phrase role="figureLabel"><anchor id="ch0054s0011a0006"/><link linkend="ch0054s0011a0005">FIGURE 10</link></phrase> Conventional biochemicals depicting positive and negative reactions for indole, urease, and ornithine decarboxylase production (left to right) by <emphasis>Haemophilus</emphasis> spp. The order of these biochemicals is indole positive, indole negative, urease positive, urease negative, ornithine decarboxylase positive, ornithine decarboxylase negative.</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0054f10.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0054s0011p0004">As is the case with indole production, in most instances, a spot urease test can be used to reliably detect urease production by most strains of<emphasis>H. influenzae</emphasis> and <emphasis>H. parainfluenzae.</emphasis> Determination of urease production with other species requires use of urease medium containing 0.1 g KH<subscript>2</subscript>PO<subscript>4</subscript>, 0.1 g K<subscript>2</subscript>HPO<subscript>4</subscript>, 0.5 g NaCl, and 0.5 ml phenol red (1:500) dissolved in 100 ml of distilled water. The pH is adjusted to 7.0 with NaOH, and 10.4 ml of a 20% aqueous solution of urea is added. After inoculation, the tube is incubated for 4 h at 35°C in ambient air and examined for a pink to red coloration, indicating a positive reaction (<link linkend="ch0054s0019s0002li0001">1</link>, <link linkend="ch0054s0019s0002li0006">6</link>) (<link linkend="ch0054s0011a0006">Fig. 10</link>).</para>
    </sect1>
    <sect1 id="ch0054s0012">
      <title>Commercial Biochemical Identification Systems</title>
      <anchor id="ch0054s0012a0001"/>
      <anchor id="ch0054s0012a0002"/>
      <para id="ch0054s0012p0001">Several commercial identification systems have been developed to identify<emphasis>Haemophilus</emphasis> spp. These systems employ a battery of conventional biochemical tests, frequently in a miniaturized form, with results available in shorter time periods than with conventional biochemical tests. The performance characteristics and identification accuracy of these commercial systems are variable (<link linkend="ch0054s0019s0002li0077">77</link>, <link linkend="ch0054s0019s0002li0082">82</link>, <link linkend="ch0054s0019s0002li0086">86</link>, <link linkend="ch0054s0019s0002li0087">87</link>). The RapID NH system (Thermo Fisher) contains 11 biochemical reaction mixtures in a microwell tray. The kit uses phosphate hydrolysis and nitrate reduction reactions to identify an isolate as belonging to the genus <emphasis>Haemophilus</emphasis> and the remaining reactions to identify the isolate to the species level and to determine the biotype of <emphasis>H. i</emphasis><emphasis>nfluenzae</emphasis>.</para>
      <para id="ch0054s0012p0002">The BBL Crystal<emphasis>Neisseria/Haemophilus</emphasis> ID system (BD) and API NH kit (bioMérieux) provide miniaturized biochemical identification schemes in a microwell tray, with results available in ≤5 h. The Crystal system employs 29 growth substrates and is predicated on measuring the substrate conversion chromogenically and fluorogenically after 5 h of incubation. The API NH kit consists of 12 dehydrated substrates and a well to detect penicillinase, and it permits identification of <emphasis>Haemophilus</emphasis> spp., <emphasis>Neisseria</emphasis> spp., and <emphasis>Moraxella</emphasis> spp. In addition to the two manual panels, one instrument-based identification system has been developed for species identification of <emphasis>Haemophilus</emphasis> spp., the <emphasis>Neisseria-Haemophilus</emphasis> identification cards for use with the Vitek 2 instrument (bioMérieux). The database supporting these cards encompasses 27 taxa, including <emphasis>Neisseria, Haemophilus, Actinobacillus, Campylobacter, Capnocytophaga, Cardiobacterium, Eikenella, Gardnerella, Kingella, Moraxella, Oligella</emphasis>, and <emphasis>Suttonella.</emphasis> Studies with the Vitek 2 system using both collections of well-characterized stock strains and clinical isolates have demonstrated identification accuracies of 90 to 95%, with results varying by species (<link linkend="ch0054s0019s0002li0087">87</link>, <link linkend="ch0054s0019s0002li0088">88</link>), but the implementation of MALDI-TOF MS has improved the accuracy of identifications, largely relegating these cards to being a backup method.</para>
      <sect2 id="ch0054s0012s0001">
        <title>MALDI-TOF MS</title>
        <anchor id="ch0054s0012s0001a0001"/>
        <anchor id="ch0054s0012s0001a0002"/>
        <para id="ch0054s0012s0001p0001">The two commercially available MALDI-TOF MS systems, the Bruker MALDI Biotyper (Bruker Daltonics, Billerica, MA) and Vitek MS (bioMérieux), include multiple<emphasis>Haemophilus</emphasis> species in their databases. The FDA-cleared Vitek MS database includes <emphasis>H. influenzae, H. parainfluenzae</emphasis>, and <emphasis>H. parahaemolyticus.</emphasis> The FDA-cleared database for the Biotyper includes the same organisms as the Vitek MS. Several additional <emphasis>Haemophilus</emphasis> species are included in each manufacturer’s research-use-only (RUO) database, but reports from these databases do not differentiate between <emphasis>H. parahaemolytics</emphasis> and <emphasis>H. paraphrohaemolyticus</emphasis> and only report <emphasis>H. parahaemolyticus</emphasis> to the group level. Studies evaluating MALDI-TOF MS with earlier database versions largely demonstrate excellent performance for HACEK group organisms, including <emphasis>Haemophilus</emphasis> spp. (<link linkend="ch0054s0019s0002li0089">89</link>, <link linkend="ch0054s0019s0002li0090">90</link>). Couturier et al. (<link linkend="ch0054s0019s0002li0086">86</link>) demonstrated that &gt;90 and &gt;98% of <emphasis>H. parainfluenzae</emphasis> and <emphasis>H. influenzae</emphasis> strains, respectively, could be identified to the species level using the Bruker MALDI Biotyper v2.0. Similarly, van Veen et al. (<link linkend="ch0054s0019s0002li0090">90</link>) demonstrated &gt;98% identification of HACEK organisms to the species level. Branda et al. (<link linkend="ch0054s0019s0002li0091">91</link>) evaluated the Vitek MS IVD (bioMérieux) and found 96 and 92% correct identification to the species level for <emphasis>H. influenzae</emphasis> and <emphasis>H. parainfluenzae</emphasis>, respectively. Powell et al. (<link linkend="ch0054s0019s0002li0092">92</link>) evaluated the Vitek MS with <emphasis>H. influenzae</emphasis> (<emphasis>n</emphasis> = 26), <emphasis>H. parainfluenzae</emphasis> (<emphasis>n</emphasis> = 20), <emphasis>H. haemolyticus</emphasis> (<emphasis>n</emphasis> = 11), and <emphasis>H. parahaemolyticus</emphasis> (<emphasis>n</emphasis> = 6). Correct species-level identification was observed for all <emphasis>H. influenzae</emphasis> and <emphasis>H. parahaemolyticus</emphasis> isolates, whereas only 90% of <emphasis>H. parainfluenzae</emphasis> isolates were correctly identified. All <emphasis>H. haemolyticus</emphasis> isolates were incorrectly identified as <emphasis>H. influenzae</emphasis>, but the authors noted that the Vitek MS database that was used for the study lacked spectra for any <emphasis>H. haemolyticus</emphasis> isolates. Nürnberg et al. tested the newer Vitek MS IVD V3 database, which contains <emphasis>H. haemolyticus</emphasis> (<emphasis>n</emphasis> = 26) and <emphasis>H. influenzae</emphasis> (<emphasis>n</emphasis> = 210) spectra, with a collection of <emphasis>H. influenzae</emphasis> (<emphasis>n</emphasis> = 236) and <emphasis>H. haemolyticus</emphasis> (<emphasis>n</emphasis> = 50) isolates (<link linkend="ch0054s0019s0002li0093">93</link>). All <emphasis>H. influenzae</emphasis> isolates were correctly identified, but only 38% of <emphasis>H. haemolyticus</emphasis> (19/50) isolates were correctly identified, with 42% incorrectly identified as <emphasis>H. influenzae</emphasis> (22/50) and 2% as <emphasis>H. parainfluenzae</emphasis> (1/50) (<link linkend="ch0054s0019s0002li0093">93</link>).</para>
        <anchor id="ch0054s0012s0001a0003"/>
        <beginpage pagenum="738"/>
        <para id="ch0054s0012s0001p0002">Comparisons of the Bruker MALDI Biotyper to the Vitek MS are limited; however, Frickmann et al. (<link linkend="ch0054s0019s0002li0094">94</link>) compared the Vitek MS RUO (bioMérieux) with both the Biotyper and fluorescence <emphasis>in situ</emphasis> hybridization for identification of <emphasis>H. influenzae, H. parainfluenzae</emphasis>, and <emphasis>H. parahaemolyticus.</emphasis> With formic acid extraction, the Biotyper identified 100% of <emphasis>H. influenzae</emphasis> (50/50), 88% of <emphasis>H. parainfluenzae</emphasis> (22/25), and 100% of <emphasis>H. parahaemolyticus</emphasis> (2/2) strains to the species level. Results were not significantly different for the Biotyper without prior formic acid extraction, although identification of <emphasis>H. parainfluenzae</emphasis> dropped to 72% (18/25) and the Biotyper missed an additional <emphasis>H. parahaemolyticus</emphasis> identification. The Vitek MS RUO identified 82% of <emphasis>H. influenzae</emphasis> (41/50), 68% of <emphasis>H. parainfluenzae</emphasis> (17/25), and 50% of <emphasis>H. parahaemolyticus</emphasis> (1/2) strains. All identifications on the Vitek MS were performed without prior formic acid extraction (<link linkend="ch0054s0019s0002li0094">94</link>). Neither system identified any of the seven <emphasis>H. haemolyticus</emphasis> strains analyzed (<link linkend="ch0054s0019s0002li0094">94</link>), likely due to poor representation of the organism in the databases. Martiny et al. (<link linkend="ch0054s0019s0002li0095">95</link>) compared the performance of the Vitek MS IVD to the Biotyper IVD and found 100% identification (<emphasis>n</emphasis> = 30) of <emphasis>H. influenzae</emphasis> by both systems. Evaluation of species other than <emphasis>H. influenzae</emphasis> in this study was limited by the lack of diversity of species included in the study (<link linkend="ch0054s0019s0002li0095">95</link>).</para>
        <para id="ch0054s0012s0001p0003">The performance of MALDI-TOF MS on<emphasis>Haemophilus</emphasis> spp. other than those discussed above has not been evaluated, and further study is warranted. One study examined the use of the Bruker MALDI Biotyper for capsule typing of Hib versus non-Hib isolates (<link linkend="ch0054s0019s0002li0096">96</link>). The authors used an initial training set of genetically diverse Hib isolates (<emphasis>n</emphasis> = 19) and non-Hib isolates (<emphasis>n</emphasis> = 10) to generate four distinct classification methods. The best model correctly identified all Hib isolates (<emphasis>n</emphasis> = 33) and 98.7% of non-Hib isolates (76 of 77), and the authors also showed that the results were 98% reproducible on another Bruker MALDI Biotyper instrument (<link linkend="ch0054s0019s0002li0096">96</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0054s0013">
      <title>Molecular Identification</title>
      <anchor id="ch0054s0013a0001"/>
      <anchor id="ch0054s0013a0002"/>
      <para id="ch0054s0013p0001">Several molecular methods, including 16S rRNA gene sequencing, next-generation sequencing, NAAT, microarrays, and fluorescence<emphasis>in situ</emphasis> hybridization, are described in the literature as being effective tools for <emphasis>Haemophilus</emphasis> sp. identification when performed on organisms recovered in culture (<link linkend="ch0054s0019s0002li0051">51</link>, <link linkend="ch0054s0019s0002li0097">97</link>–<link linkend="ch0054s0019s0002li0099">99</link>).</para>
      <para id="ch0054s0013p0002">Molecular targets for detection and identification of<emphasis>Haemophilus</emphasis> spp. are numerous. Previous studies have described detection of <emphasis>H. influenzae</emphasis> using the <emphasis>cap</emphasis> locus (which includes the capsule <emphasis>bexA</emphasis>) (<link linkend="ch0054s0019s0002li0053">53</link>, <link linkend="ch0054s0019s0002li0062">62</link>, <link linkend="ch0054s0019s0002li0100">100</link>, <link linkend="ch0054s0019s0002li0101">101</link>), the 16S rRNA gene (<link linkend="ch0054s0019s0002li0051">51</link>, <link linkend="ch0054s0019s0002li0062">62</link>, <link linkend="ch0054s0019s0002li0102">102</link>, <link linkend="ch0054s0019s0002li0103">103</link>), the insertion-like sequence (IS<emphasis>1016</emphasis>) (<link linkend="ch0054s0019s0002li0101">101</link>), the fumarate reductase iron-sulfur gene B (<emphasis>frdB</emphasis>) (<link linkend="ch0054s0019s0002li0104">104</link>), the manganese-dependent superoxide dismutase gene (<emphasis>sodA</emphasis>) (<link linkend="ch0054s0019s0002li0105">105</link>), and the outer membrane protein P6 gene (<emphasis>ompP6</emphasis>) (<link linkend="ch0054s0019s0002li0062">62</link>, <link linkend="ch0054s0019s0002li0102">102</link>, <link linkend="ch0054s0019s0002li0106">106</link>). Many of these targets are assessed using NAATs (real time or traditional), microarrays, or sequencing to identify the organism. Widely utilized for sequencing, 16S rRNA gene generally resolves <emphasis>Haemophilus</emphasis> spp. to the species level; however, identification of <emphasis>H. influenzae, H. aegyptius</emphasis>, and <emphasis>H. influenzae</emphasis> biogroup aegyptius can be problematic due to the high degree of homology in their sequences. In these instances, sequencing of other targets, such as <emphasis>rpoD</emphasis>, should be considered, or the use of combined sequencing and biochemical studies may be used.</para>
      <para id="ch0054s0013p0003">Application of highly multiplex disease-state panels, such as the FilmArray (bioMérieux), Verigene (Nanosphere, Inc., Northbrook, IL), or ePlex (GenMark Diagnostics, Inc., Carlsbad, CA) to positive blood cultures has demonstrated a reduction in lengths of patients’ hospital stays and enhanced antimicrobial stewardship (<link linkend="ch0054s0019s0002li0107">107</link>). Application of these technologies to the identification of <emphasis>Haemophilus</emphasis> spp. from positive blood cultures offers a significant reduction in turnaround time to a result. Limited clinical data are available on the performance of the BioFire FilmArray blood culture identification panel, but in a large multicenter study, all eight <emphasis>H. influenzae</emphasis> isolates were correctly identified, with no false-positive results observed (<link linkend="ch0054s0019s0002li0108">108</link>). The newer BioFire FilmArray blood culture identification 2 panel (bioMérieux) still includes <emphasis>H. influenzae</emphasis>, but limited performance data are available. Holma et al. examined 103 unique patient positive blood cultures and found 100% sensitivity (<emphasis>n</emphasis> = 1) and specificity (<emphasis>n</emphasis> = 102) for <emphasis>H. influenzae</emphasis> (<link linkend="ch0054s0019s0002li0109">109</link>). A multicenter evaluation of the investigational-use-only version of the GenMark Dx ePlex panel for Gram-negative organisms found 100% sensitivity (<emphasis>n</emphasis> = 55) and specificity (<emphasis>n</emphasis> = 1,648) for <emphasis>H. influenzae</emphasis> in clinical and contrived samples (<link linkend="ch0054s0019s0002li0110">110</link>). More data are needed to assess the performance of these panels.</para>
    </sect1>
    <sect1 id="ch0054s0014">
      <title>Problems in Identification</title>
      <anchor id="ch0054s0014a0001"/>
      <anchor id="ch0054s0014a0002"/>
      <para id="ch0054s0014p0001">A significant challenge in the species identification of<emphasis>H. influenzae, H. aegyptius</emphasis>, and <emphasis>H. influenzae</emphasis> biogroup aegyptius is a lack of biochemical diversity and sequence divergence (<link linkend="ch0054s0019s0002li0001">1</link>, <link linkend="ch0054s0019s0002li0006">6</link>, <link linkend="ch0054s0019s0002li0008">8</link>). Biochemical profiling and standard 16S rRNA gene sequencing fail to adequately distinguish these organisms (<link linkend="ch0054s0019s0002li0001">1</link>, <link linkend="ch0054s0019s0002li0006">6</link>, <link linkend="ch0054s0019s0002li0008">8</link>), necessitating use of alternative sequencing targets, such as those mentioned in the previous section, or a combination of sequencing and biochemical testing. This is problematic, since <emphasis>H. aegyptius</emphasis> lacks the potential to cause Brazilian purpuric fever, while strains of <emphasis>H. influenzae</emphasis> biogroup aegyptius cause the disease. Xylose fermentation by most <emphasis>H. influenzae</emphasis> isolates combined with the lower growth rate of <emphasis>H. influenzae</emphasis> biotype aegyptius and the ability of <emphasis>H. aegyptius</emphasis> to agglutinate human erythrocytes may be of some value in distinguishing these organisms (<link linkend="ch0054s0019s0002li0001">1</link>, <link linkend="ch0054s0019s0002li0008">8</link>).</para>
      <anchor id="ch0054s0014a0003"/>
      <beginpage pagenum="739"/>
      <sect2 id="ch0054s0014s0001">
        <title>TYPING SYSTEMS</title>
        <anchor id="ch0054s0014s0001a0001"/>
        <anchor id="ch0054s0014s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0054s0015">
      <title>Capsular Serotyping and Biotyping</title>
      <anchor id="ch0054s0015a0001"/>
      <anchor id="ch0054s0015a0002"/>
      <para id="ch0054s0015p0001">The capsular antigen of<emphasis>H. influenzae</emphasis> is a principal virulence determinant of this organism. Six capsular antigens have been recognized, each characterized by a distinct carbohydrate chemical composition and given a letter designation from a to f. Prior to the introduction of the pediatric HIB vaccine, capsular type b strains were recovered from human clinical specimens most often. However, today, at least among populations in which there is widespread use of the HIB vaccine, non-b strains occur at different frequencies. For this reason, it may be instructive to know the capsular serotypes of <emphasis>H. influenzae</emphasis> strains recovered from clinical specimens, especially those that are representative of invasive disease. This may be accomplished using both phenotypic and genotypic methods.</para>
      <para id="ch0054s0015p0002">Capsular serotyping of<emphasis>H. influenzae</emphasis> is best accomplished using a slide agglutination assay that employs polyclonal antisera specifically reactive with each of the six capsular antigens (<link linkend="ch0054s0019s0002li0006">6</link>, <link linkend="ch0054s0019s0002li0111">111</link>, <link linkend="ch0054s0019s0002li0112">112</link>). It is advisable to perform serotyping as soon as possible after isolation of <emphasis>H. influenzae</emphasis>, because the amount of capsular antigen produced may diminish over time, especially with repeated subculture.</para>
      <para id="ch0054s0015p0003">As noted above, based on three phenotypic properties, the production of indole, ornithine decarboxylase, and urease, strains of<emphasis>H. influenzae</emphasis> and <emphasis>H. parainfluenzae</emphasis> can be distinguished into multiple biotypes (<link linkend="ch0054s0001s0002a0019">Table 2</link>). Also, as outlined above, at least with <emphasis>H. influenzae</emphasis>, certain biotypes have been found to have specific disease associations.</para>
    </sect1>
    <sect1 id="ch0054s0016">
      <title>Typing by Molecular Methods</title>
      <anchor id="ch0054s0016a0001"/>
      <anchor id="ch0054s0016a0002"/>
      <para id="ch0054s0016p0001">Molecular methods have the advantage of enhanced sensitivity and specificity (<link linkend="ch0054s0019s0002li0113">113</link>) due to the use of standardized techniques and a lack of false-positive reactions observed with nonencapsulated strains in slide agglutination tests.</para>
      <para id="ch0054s0016p0002">Capsular typing of<emphasis>H. influenzae</emphasis> can also be accomplished using various molecular methods. Most assays rely on amplification of genes in the <emphasis>cap</emphasis> locus, the outer membrane protein D gene (<emphasis>glpQ</emphasis>), the capsule-producing gene (<emphasis>bexA</emphasis>), the 16S rRNA gene, and the insertion-like sequence (<link linkend="ch0054s0019s0002li0114">114</link>). One algorithm used detection of the <emphasis>cap</emphasis> genes to determine capsular serotypes a through f, while the capsule-producing gene, <emphasis>bexA</emphasis>, was used to separate strains that produce capsule from those that do not (<link linkend="ch0054s0019s0002li0114">114</link>). Detection of the <emphasis>ompP2</emphasis> (outer membrane lipoprotein P2) gene was used as a control. With this system, both a conventional and a real-time NAAT were found to be more sensitive than a slide agglutination test for serotyping <emphasis>H. influenzae</emphasis> (<link linkend="ch0054s0019s0002li0114">114</link>).</para>
      <para id="ch0054s0016p0003">As with the<emphasis>Enterobacterales</emphasis>, pulsed-field gel electrophoresis was considered the gold standard for strain typing of <emphasis>Haemophilus</emphasis>, before being displaced by whole-genome sequencing (WGS). Pulsed-field gel electrophoresis demonstrates excellent separation of clones but is laborious and time-consuming (<link linkend="ch0054s0019s0002li0115">115</link>–<link linkend="ch0054s0019s0002li0117">117</link>). Other molecular methods for typing have also been applied to <emphasis>Haemophilus</emphasis> spp. Studies evaluating repetitive-element sequence-based NAAT using intergenic dyad sequence (IDS)-specific primers (IDS-PCR) for nonencapsulated <emphasis>Haemophilus</emphasis> strains demonstrated excellent separation of NTHi strains (<link linkend="ch0054s0019s0002li0116">116</link>). Other typing technologies applied to <emphasis>Haemophilus</emphasis> include ribotyping, restriction fragment length polymorphism analysis, multilocus enzyme electrophoresis, randomly amplified polymorphic DNA profile analysis, and multilocus sequence typing (MLST) (<link linkend="ch0054s0019s0002li0116">116</link>). MLST offers the advantage of superior discriminatory power because it combines sequence typing of seven housekeeping genes with results that can readily be compared between laboratories (<link linkend="ch0054s0019s0002li0008">8</link>). The publicly available PubMLST database includes MLST and other sequencing data (i.e., finished genomes to single gene sequences) for <emphasis>H. influenzae</emphasis>, including 6,763 isolate sequences, and 2,757 genomes as of mid-2022 (<ulink url="https://pubmlst.org/organisms/haemophilus-influenzae">https://pubmlst.org/organisms/haemophilus-influenzae</ulink>). As useful as classical MLST schemes have been as a universal standardized system for organizing the great diversity within bacteria, these schemes are based on the analysis of a small fraction of the genome. Consequently, classic MLST-based approaches are not always able to make the distinctions within clonal lineages that are needed for epidemiologic purposes. Analysis of the whole genome provides a more complete source of information from which to reconstruct phylogenies and to compare strains, and when applied to the MLST method, in which the unit of analysis is individual alleles, this can be expanded to whole-genome data in a variety of ways.</para>
      <para id="ch0054s0016p0004">WGS offers the promise of detection of an organism, classification of antimicrobial resistance factors, and typing of the organism in a single assay. Furthermore, with turnaround time for sequencing and annotation of the sequence decreasing to &lt;24 h, real-time identification of outbreaks will become the standard of care. An investigation by Power et al. (<link linkend="ch0054s0019s0002li0118">118</link>) sequenced the genome of 85 strains of <emphasis>H. influenzae</emphasis> and aligned the sequences by Mauve alignment. The study demonstrated distinct clusters of strains associated with serotype and regions of significant variation in sequence, likely due to transformation events. This preliminary work demonstrates the principle of typing based on genome sequence and may result in significant improvement in our ability to resolve strains into sequence types with much greater precision (<link linkend="ch0054s0019s0002li0118">118</link>). Supporting the use of WGS for strain typing, De Chiara et al. (<link linkend="ch0054s0019s0002li0119">119</link>) sequenced 97 isolates from a UK strain collection and found distinct evolutionary clades associated with local NTHi infections, supporting clonal evolution with the majority of genetic information transmitted vertically within lineages. This is supported by the results of an Australian WGS-MLST study that found that encapsulated isolates were largely clonal; however, by MLST and single-nucleotide-polymorphism typing, NTHi isolates displayed high genetic variability with no dominant clone observed (<link linkend="ch0054s0019s0002li0120">120</link>). Directly utilizing WGS to investigate the clonal spread of the ST14CC-PBP3IIb/A strain of <emphasis>H. influenzae</emphasis> in Sweden, Månsson et al. (<link linkend="ch0054s0019s0002li0121">121</link>) evaluated 3,262 genomes sequenced from respiratory or invasive isolates occurring from 2010 to 2012. They found that isolates belonging to ST14CC constituted 26% of the NTHi strains isolated and that patients infected with these strains had higher rates of hospitalization than those with strains without the PBP3 mutations. Strain type was also overlaid on mapping of patients’ addresses to demonstrate a dynamic geographical spread of the β-lactam-resistant (PBP3IIb/A) strain. As the number of available genome sequences continues to increase and WGS is adopted by a greater number of clinical and public health labs, it is likely that older typing systems will be supplanted by genomic methods, with improved bioinformatic tools and automation of WGS-based typing.</para>
      <para id="ch0054s0016p0005">A comprehensive review of the classical typing methods for<emphasis>Haemophilus</emphasis> spp. is provided by Harrison et al. (<link linkend="ch0054s0019s0002li0113">113</link>).</para>
      <sect2 id="ch0054s0016s0001">
        <title>SEROLOGIC TESTS</title>
        <anchor id="ch0054s0016s0001a0001"/>
        <anchor id="ch0054s0016s0001a0002"/>
        <para id="ch0054s0016s0001p0001">Antibody tests have been developed for the detection of<emphasis>Haemophilus</emphasis> antibodies; however, they are of little clinical value and are not readily available. Studies evaluating the performances of the enzyme-linked immunosorbent assays (<link linkend="ch0054s0019s0002li0122">122</link>) and immunofluorescent assays (<link linkend="ch0054s0019s0002li0123">123</link>) have been conducted; however, because immunity to <emphasis>Haemophilus</emphasis> spp. is derived from an eclectic combination of antibodies against the <emphasis>H. influenzae</emphasis> capsule and membrane proteins, assays to detect a single class of antibody are of little value. Further complicating the use of <emphasis>Haemophilus</emphasis> serology is the individual variation in antibody level (many adults have undetectable antibody levels), avidity, and persistence (<link linkend="ch0054s0019s0002li0018">18</link>).</para>
        <anchor id="ch0054s0016s0001a0003"/>
        <beginpage pagenum="740"/>
      </sect2>
      <sect2 id="ch0054s0016s0002">
        <title>ANTIMICROBIAL SUSCEPTIBILITIES</title>
        <anchor id="ch0054s0016s0002a0001"/>
        <anchor id="ch0054s0016s0002a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0054s0017">
      <title>Resistance Rates</title>
      <anchor id="ch0054s0017a0001"/>
      <anchor id="ch0054s0017a0002"/>
      <para id="ch0054s0017p0001"><emphasis>H. influenzae</emphasis> may produce one of two β-lactamases, TEM-1 and ROB-1. Both enzymes are plasmid associated, are extracellular, and are produced constitutively in large amounts (<link linkend="ch0054s0019s0002li0124">124</link>). β-Lactamase-producing strains should be considered resistant to ampicillin and amoxicillin (<link linkend="ch0054s0019s0002li0125">125</link>).</para>
      <para id="ch0054s0017p0002">The prevalence of β-lactamase-producing NTHi declined in the United States during the 1990s, possibly due to the increased use, beginning in the early 1990s, of non-β-lactam antimicrobials, such as the macrolides and fluoroquinolones, in the empiric management of infections such as otitis media, sinusitis, and bronchopulmonary infections, i.e., infections with which NTHi is most often associated (<link linkend="ch0054s0019s0002li0126">126</link>). Because of this therapeutic paradigm shift, β-lactams such as ampicillin and amoxicillin were used less often, with resulting diminished selective pressure on the emergence and persistence of β-lactamase-producing NTHi. This trend toward decreasing rates of β-lactamase-producing NTHi, however, seems paradoxically to have changed, possibly because of the widespread use of pediatric pneumococcal conjugate antigen vaccines. As <emphasis>S. pneumoniae</emphasis> has become less common as a cause of acute otitis media, NTHi has reemerged as the most common cause of the infection, with a proportionate increase in rates of β-lactamase-mediated ampicillin resistance (<link linkend="ch0054s0019s0002li0127">127</link>). In the United States, ~27% of clinical isolates of NTHi produce β-lactamase (<link linkend="ch0054s0019s0002li0128">128</link>).</para>
      <para id="ch0054s0017p0003">β-Lactamase-producing strains of<emphasis>H. influenzae</emphasis> remain susceptible to oral and parenteral cephalosporins and carbapenems (<link linkend="ch0054s0019s0002li0129">129</link>–<link linkend="ch0054s0019s0002li0131">131</link>). They are usually susceptible (see below) to combination agents in which a β-lactamase inhibitor, such as clavulanate, sulbactam, or tazobactam, is combined with a β-lactam agent (<link linkend="ch0054s0019s0002li0130">130</link>).</para>
      <para id="ch0054s0017p0004">Strains of<emphasis>H. influenzae</emphasis> that fail to produce β-lactamase but for which the MICs of ampicillin and amoxicillin are elevated have been described (<link linkend="ch0054s0019s0002li0132">132</link>). These strains, which are referred to as β-lactamase negative and ampicillin resistant (BLNAR), have altered penicillin-binding proteins, which abrogates the binding of drugs such as ampicillin and amoxicillin to their cell wall targets, resulting in elevated MICs (<link linkend="ch0054s0019s0002li0133">133</link>, <link linkend="ch0054s0019s0002li0134">134</link>). The activities of cephalosporins are also diminished with such strains. If one uses an ampicillin MIC of ≥4 μg/ml to define resistance within <emphasis>Haemophilus</emphasis> spp., as is recommended by the Clinical and Laboratory Standards Institute (CLSI) (<link linkend="ch0054s0019s0002li0125">125</link>), the prevalence of BLNAR strains of <emphasis>H. influenzae</emphasis> was 1.4% in the United States (<link linkend="ch0054s0019s0002li0130">130</link>), whereas higher BLNAR prevalence has been observed in Japan (20.8% in 2017 for pediatric patients) (<link linkend="ch0054s0019s0002li0129">129</link>) and Europe (9.6% in 2002/2003) (<link linkend="ch0054s0019s0002li0135">135</link>). Additionally, β-lactamase-positive, amoxicillin-clavulanate-resistant (BLPACR) isolates have been described, accounting for 2.3% of <emphasis>H. influenzae</emphasis> β-lactamase positive isolates tested from the United States in 2019 (<link linkend="ch0054s0019s0002li0130">130</link>) and 1.9% of isolates tested from Japan in 2017 (<link linkend="ch0054s0019s0002li0129">129</link>).</para>
      <para id="ch0054s0017p0005">Among other antimicrobials relevant to the management of<emphasis>Haemophilus</emphasis> infections, with the exception of trimethoprim-sulfamethoxazole (TMP-SMX), resistance rates remain at levels of &lt;1% for <emphasis>H. influenzae</emphasis> isolates from the United States and Europe (<link linkend="ch0054s0019s0002li0130">130</link>, <link linkend="ch0054s0019s0002li0131">131</link>). These antimicrobials include cephalosporins, macrolides, fluoroquinolones, and tetracycline. TMP-SMX resistance rates approach ~30% (<link linkend="ch0054s0019s0002li0130">130</link>). For <emphasis>H. influenzae</emphasis> isolates from Asia and Latin America, slightly higher rates of resistance were observed with tetracycline, levofloxacin, and azithromycin (<link linkend="ch0054s0019s0002li0136">136</link>).</para>
    </sect1>
    <sect1 id="ch0054s0018">
      <title>Susceptibility Test Methods</title>
      <anchor id="ch0054s0018a0001"/>
      <anchor id="ch0054s0018a0002"/>
      <para id="ch0054s0018p0001">β-Lactamase production by<emphasis>Haemophilus</emphasis> spp. can be determined rapidly with either a chromogenic cephalosporin spot test or an acidimetric penicillinase assay, as described in <ulink url="ch0093#ch0093s0001">chapter 75</ulink> in this <emphasis>Manual.</emphasis> Because the β-lactamases of <emphasis>H. influenzae</emphasis> are extracellular, constitutive, and produced in large amounts, assuming that the test is performed carefully and with adequate positive and negative controls, both methods yield reliable results.</para>
      <para id="ch0054s0018p0002">Disk diffusion susceptibility tests can be performed using<emphasis>Haemophilus</emphasis> test medium agar, with incubation of plates for 16 to 18 h at 35°C in 5% CO<subscript>2</subscript>, as described by CLSI. Zone diameter interpretive criteria have been developed for 42 antimicrobial agents by CLSI only for <emphasis>H. influenzae</emphasis> and <emphasis>H. parainfluenzae</emphasis> (<link linkend="ch0054s0019s0002li0125">125</link>). The European Committee on Antimicrobial Susceptibility Testing (EUCAST) has disk diffusion susceptibility testing criteria using Mueller-Hinton agar with 5% defibrinated horse blood supplemented with 20 mg/liter β-NAD, with incubation of plates for 18 ± 2 h at 35°C in 5% CO<subscript>2</subscript> (<ulink url="http://eucast.org/clinical_breakpoints/">http://eucast.org/clinical_breakpoints/</ulink>). EUCAST has zone diameter interpretive criteria for 30 antimicrobial agents only for <emphasis>H. influenzae</emphasis> isolates (<ulink url="http://eucast.org/clinical_breakpoints/">http://eucast.org/clinical_breakpoints/</ulink>). The details of disk diffusion susceptibility tests are presented in <ulink url="ch0091#ch0091s0001">chapter 73</ulink> of this <emphasis>Manual</emphasis>.</para>
      <para id="ch0054s0018p0003">MICs can be determined with<emphasis>Haemophilus</emphasis> spp. by broth microdilution (BMD). The CLSI advocates the use of <emphasis>Haemophilus</emphasis> test medium broth when determining MICs by the BMD method (<link linkend="ch0054s0019s0002li0137">137</link>). Following inoculation, trays are incubated for 20 to 24 h in ambient air at 35°C prior to determination of MICs; CLSI has developed MIC interpretive criteria for 46 antimicrobial agents for <emphasis>H. influenzae</emphasis> and <emphasis>H. parainfluenzae</emphasis> (<link linkend="ch0054s0019s0002li0125">125</link>). EUCAST has MIC susceptibility testing criteria using Mueller-Hinton broth with 5% lysed horse blood supplemented with 20 mg/liter β-NAD, with incubation of plates for 18 ± 2 h at 35°C in sealed plates (<ulink url="http://eucast.org/clinical_breakpoints/">http://eucast.org/clinical_breakpoints/</ulink>). EUCAST has MIC interpretive criteria only for <emphasis>H. influenzae</emphasis> isolates to 34 antimicrobial agents (<ulink url="http://eucast.org/clinical_breakpoints/">http://eucast.org/clinical_breakpoints/</ulink>). The details of BMD MIC tests are presented in <ulink url="ch0091#ch0091s0001">chapter 73</ulink> of this <emphasis>Manual.</emphasis> Unfortunately, there are almost no published data validating the use of the gradient diffusion method with <emphasis>Haemophilus</emphasis> spp., and therefore, the use of this method is not recommended for susceptibility tests with this organism group.</para>
      <para id="ch0054s0018p0004">Susceptibility tests with clinical isolates of<emphasis>H. ducreyi</emphasis> should not be attempted in routine clinical microbiology laboratories, because standardized susceptibility test methods of proven reliability for this organism have not yet been developed. Similarly, instrument-based susceptibility tests for other <emphasis>Haemophilus</emphasis> spp., including <emphasis>H. influenzae</emphasis>, have not been proven to be effective and are not recommended for testing this organism group.</para>
      <anchor id="ch0054s0018a0003"/>
      <beginpage pagenum="741"/>
      <para id="ch0054s0018p0005">Irrespective of the method used for performing susceptibility tests with<emphasis>Haemophilus</emphasis> spp., it is essential that adequate quality control be applied using two <emphasis>H. influenzae</emphasis> quality control strains, ATCC 49247 and ATCC 49766.</para>
    </sect1>
    <sect1 id="ch0054s0019">
      <title>Susceptibility Testing Algorithm</title>
      <anchor id="ch0054s0019a0001"/>
      <anchor id="ch0054s0019a0002"/>
      <para id="ch0054s0019p0001">Susceptibility testing with clinical isolates of<emphasis>Haemophilus</emphasis> spp. should be applied only to isolates known to be of clinical significance. Further, in most instances, only a β-lactamase assay as a means for assessing the activities of ampicillin and amoxicillin need be performed. The prevalence of BLNAR strains of <emphasis>H. influenzae</emphasis> and their resistance to other agents that are commonly used to treat the types of infections with which <emphasis>Haemophilus</emphasis> spp. are associated are simply too low, depending on location, to justify routine testing. One exception might be resistance to TMP-SMX. This agent, however, is used almost exclusively for oral therapy of community-acquired respiratory tract infections that are invariably managed empirically without performance of laboratory studies aimed at elucidating the specific cause of an individual patient’s infection. In other words, in settings where knowledge of the activity profile of TMP-SMX versus <emphasis>H. influenzae</emphasis> could be of value, rarely, if ever, is a patient isolate available for testing. In those rare circumstances where the assessment of the activities of agents other than ampicillin or amoxicillin is found to be warranted, either a disk diffusion susceptibility test or a BMD MIC test should be performed.</para>
      <sect2 id="ch0054s0019s0001">
        <title>EVALUATION, INTERPRETATION, AND REPORTING OF RESULTS</title>
        <anchor id="ch0054s0019s0001a0001"/>
        <anchor id="ch0054s0019s0001a0002"/>
        <para id="ch0054s0019s0001p0001">The genus<emphasis>Haemophilus</emphasis> is a diverse group of organisms that may exist as part of the normal bacterial microbiota of healthy humans or may be associated with significant disease. As a result, simple recovery of <emphasis>Haemophilus</emphasis> from a human clinical sample may not always indicate that the organism is clinically significant. In the following three circumstances, recovery of <emphasis>Haemophilus</emphasis> spp. in the laboratory is pathognomonic: (i) isolates from normally sterile sites, including blood cultures, that are clinically compatible with illness; (ii) <emphasis>H. ducreyi</emphasis> is recovered from genital tract specimens obtained from patients with genital ulcers; and (iii) isolates of <emphasis>H. aegyptius</emphasis> from conjunctival specimens that are obtained from patients with exudative inflammation of the conjunctiva.</para>
        <para id="ch0054s0019s0001p0002">Recovery of<emphasis>Haemophilus</emphasis> spp. from specimens that may be contaminated with commensal members of the microbiota represents a situation in which the clinical significance of the isolate must be questioned. This is often the case, for example, with isolates from respiratory tract sites. In such instances, the quantity of organism recovered—both the absolute quantity and the quantity of the isolate in comparison to quantities of other organisms recovered from the specimen—is of limited value in assessing clinical significance. It may be helpful to try to assess the quality of the specimen, as is possible, for example, with expectorated sputa and endotracheal aspirates. It may also be instructive to compare the results of a given culture with results obtained from previous and subsequent cultures from the same site. Generally speaking, repetitive recovery of the same organism from multiple specimens representative of a specific infectious disease process in an individual patient can be taken as an indication of clinical significance. And finally, it must be recognized that in some cases, it simply is not possible to know with certainty whether a given isolate of <emphasis>Haemophilus</emphasis> spp. is clinically significant. In such instances, active dialog with health care providers is encouraged.</para>
        <para id="ch0054s0019s0001p0003">The genus<emphasis>Haemophilus</emphasis> is a diverse collection of organisms that both colonize the human body and cause infections ranging from otitis media to sepsis. Use of appropriate enrichment media and next-generation identification typing techniques is helping us to better understand epidemics and ensure early and appropriate patient management.</para>
      </sect2>
      <sect2 id="ch0054s0019s0002">
        <title>REFERENCES</title>
        <anchor id="ch0054s0019s0002a0001"/>
        <anchor id="ch0054s0019s0002a0002"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0054s0019s0002li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Kilian M, Biberstein EL.</emphasis> 1984. Genus II. Haemophilus Winslow, Broadhurst, Krumwiede, Rogers and Smith 1917, 561, p 4. <citetitle><emphasis>In</emphasis></citetitle> Bergey DH, Krieg NR, Holt JG (ed), <citetitle><emphasis>Bergey’s Manual of Systematic Bacteriology.</emphasis></citetitle> Williams &amp; Wilkins, Baltimore, MD.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Zheng ML, Li LH, Liu B, Lin YB, Zhang XT, Chen C, Qu PH, Zeng J.</emphasis> 2020. <citetitle><emphasis>Haemophilus seminalis</emphasis></citetitle> sp. nov., isolated from human semen. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">70:</emphasis>2588–2595.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Nørskov-Lauritsen N, Bruun B, Andersen C, Kilian M.</emphasis> 2012. Identification of haemolytic <citetitle><emphasis>Haemophilus</emphasis></citetitle> species isolated from human clinical specimens and description of <citetitle><emphasis>Haemophilus sputorum</emphasis></citetitle> sp. nov. <citetitle><emphasis>Int J Med Microbiol</emphasis></citetitle> <emphasis role="strong">302:</emphasis>78–83.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Nørskov-Lauritsen N, Kilian M.</emphasis> 2006. Reclassification of <citetitle><emphasis>Actinobacillus actinomycetemcomitans</emphasis></citetitle>, <citetitle><emphasis>Haemophilus aphrophilus</emphasis></citetitle>, <citetitle><emphasis>Haemophilus paraphrophilus</emphasis></citetitle> and <citetitle><emphasis>Haemophilus segnis</emphasis></citetitle> as <citetitle><emphasis>Aggregatibacter actinomycetemcomitans</emphasis></citetitle> gen. nov., comb. nov., <citetitle><emphasis>Aggregatibacter aphrophilus</emphasis></citetitle> comb. nov. and <citetitle><emphasis>Aggregatibacter segnis</emphasis></citetitle> comb. nov., and emended description of <citetitle><emphasis>Aggregatibacter aphrophilus</emphasis></citetitle> to include V factor-dependent and V factor-independent isolates. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>2135–2146.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Nørskov-Lauritsen N.</emphasis> 2014. Classification, identification, and clinical significance of <citetitle><emphasis>Haemophilus</emphasis></citetitle> and <citetitle><emphasis>Aggregatibacter</emphasis></citetitle> species with host specificity for humans. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">27:</emphasis>214–240.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Kilian M.</emphasis> 2005. Genus II. <citetitle><emphasis>Haemophilus</emphasis></citetitle> Winslow, Broadhurst, Krumwiede, Rogers and Smith 1917, 561, p 883–904. <citetitle><emphasis>In</emphasis></citetitle> Garrity GM (ed), <citetitle><emphasis>Bergey’s Manual of Systematic Bacteriology</emphasis></citetitle>, vol 2. Springer, New York, NY.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Flesher AR, Insel RA.</emphasis> 1978. Characterization of lipopolysaccharide of <citetitle><emphasis>Haemophilus influenzae. J Infect Dis</emphasis></citetitle> <emphasis role="strong">138:</emphasis>719–730.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Kilian M.</emphasis> 2007. <citetitle><emphasis>Haemophilus. In</emphasis></citetitle> Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller M (ed), <citetitle><emphasis>Manual of Clinical Microbiology</emphasis></citetitle>, 9th ed. ASM Press, Washington, DC.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Scott FA, German C, Boswick JA Jr.</emphasis> 1981. <citetitle><emphasis>Hemophilus influenzae</emphasis></citetitle> cellulitis of the hand. <citetitle><emphasis>J Hand Surg Am</emphasis></citetitle> <emphasis role="strong">6:</emphasis>506–509.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Erwin AL, Smith AL.</emphasis> 2007. Nontypeable <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle>: understanding virulence and commensal behavior. <citetitle><emphasis>Trends Microbiol</emphasis></citetitle> <emphasis role="strong">15:</emphasis>355–362.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Doern GV, Chapin KC.</emphasis> 1987. Determination of biotypes of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> and <citetitle><emphasis>Haemophilus parainfluenzae</emphasis></citetitle> a comparison of methods and a description of a new biotype (VIII) of <citetitle><emphasis>H. parainfluenzae. Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">7:</emphasis>269–272.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Kilian M, Schiott CR.</emphasis> 1975. Haemophili and related bacteria in the human oral cavity. <citetitle><emphasis>Arch Oral Biol</emphasis></citetitle> <emphasis role="strong">20:</emphasis>791–796.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Kuklinska D, Kilian M.</emphasis> 1984. Relative proportions of <citetitle><emphasis>Haemophilus</emphasis></citetitle> species in the throat of healthy children and adults. <citetitle><emphasis>Eur J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">3:</emphasis>249–252.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Liljemark WF, Bloomquist CG, Uhl LA, Schaffer EM, Wolff LF, Pihlstrom BL, Bandt CL.</emphasis> 1984. Distribution of oral <citetitle><emphasis>Haemophilus</emphasis></citetitle> species in dental plaque from a large adult population. <citetitle><emphasis>Infect Immun</emphasis></citetitle> <emphasis role="strong">46:</emphasis>778–786.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Sims W.</emphasis> 1970. Oral haemophili. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">3</emphasis><emphasis role="strong">:</emphasis>615–625.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Hawkes S, West B, Wilson S, Whittle H, Mabey D.</emphasis> 1995. Asymptomatic carriage of <citetitle><emphasis>Haemophilus ducreyi</emphasis></citetitle> confirmed by the polymerase chain reaction. <citetitle><emphasis>Genitourin Med</emphasis></citetitle> <emphasis role="strong">71</emphasis><emphasis role="strong">:</emphasis>224–227.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0017" role="bibliographyEntry">
            <anchor id="ch0054s0019s0002a0003"/>
            <para>17.<emphasis role="strong">Trees DL, Morse SA.</emphasis> 1995. Chancroid and <citetitle><emphasis>Haemophilus ducreyi</emphasis></citetitle>: an update. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">8:</emphasis>357–375.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Murphy TF.</emphasis> 2005. <citetitle><emphasis>Haemophilus</emphasis></citetitle> Infections, p 2661–2669. <citetitle><emphasis>In</emphasis></citetitle> Mandell GL, Bennett JE, Dolin R (ed), <citetitle><emphasis>Principles and Practices of Infectious Diseases</emphasis></citetitle>, 6th ed, vol 2. Elsevier, Philadelphia, PA.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0019" role="bibliographyEntry">
            <para>19. 2021. Epidemiology of invasive<citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> serotype a disease—United States, 2008-2017. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">40:</emphasis>1028.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Morris SK, Moss WJ, Halsey N.</emphasis> 2008. <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> type b conjugate vaccine use and effectiveness. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">8:</emphasis>435–443.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">St Geme JW III.</emphasis> 1993. Nontypeable <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> disease: epidemiology, pathogenesis, and prospects for prevention. <citetitle><emphasis>Infect Agents Dis</emphasis></citetitle> <emphasis role="strong">2:</emphasis>1–16.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Raymond J, Armand-Lefevre L, Moulin F, Dabernat H, Commeau A, Gendrel D, Berche P.</emphasis> 2001. Nasopharyngeal colonization by <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> in children living in an orphanage. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">20:</emphasis>779–784.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">DeMuri GP, Gern JE, Eickhoff JC, Lynch SV, Wald ER.</emphasis> 2018. Dynamics of bacterial colonization with S<citetitle><emphasis>treptococcus pneumoniae</emphasis></citetitle>, <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle>, and <citetitle><emphasis>Moraxella catarrhalis</emphasis></citetitle> during symptomatic and asymptomatic viral upper respiratory tract infection. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">66:</emphasis>1045–1053.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Slack MPE, Cripps AW, Grimwood K, Mackenzie GA, Ulanova M.</emphasis> 2021. Invasive <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> infections after 3 decades of Hib protein conjugate vaccine use. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">34</emphasis><emphasis role="strong">:</emphasis>e0002821.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Dworkin MS, Park L, Borchardt SM.</emphasis> 2007. The changing epidemiology of invasive <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> disease, especially in persons ≥65 years old. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">44</emphasis><emphasis role="strong">:</emphasis>810–816.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">MacNeil JR, Cohn AC, Farley M, Mair R, Baumbach J, Bennett N, Gershman K, Harrison LH, Lynfield R, Petit S, Reingold A, Schaffner W, Thomas A, Coronado F, Zell ER, Mayer LW, Clark TA, Messonnier NE.</emphasis> 2011. Current epidemiology and trends in invasive <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> disease—United States, 1989-2008. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">53:</emphasis>1230–1236.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Fattorini L, Creti R, Palma C, Pantosti A, Unit of Antibiotic Resistance and Special Pathogens, Unit of Antibiotic Resistance and Special Pathogens of the Department of Infectious Diseases, Istituto Superiore di Sanità, Rome.</emphasis> 2020. Bacterial coinfections in COVID-19: an underestimated adversary. <citetitle><emphasis>Ann Ist Super Sanita</emphasis></citetitle> <emphasis role="strong">56:</emphasis>359–364.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Murphy TF, Bernstein JM, Dryja DM, Campagnari AA, Apicella MA.</emphasis> 1987. Outer membrane protein and lipooligosaccharide analysis of paired nasopharyngeal and middle ear isolates in otitis media due to nontypable <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle>: pathogenetic and epidemiological observations. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">156:</emphasis>723–731.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Oberhofer TR, Back AE.</emphasis> 1979. Biotypes of <citetitle><emphasis>Haemophilus</emphasis></citetitle> encountered in clinical laboratories. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">10:</emphasis>168–174.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Chandran A, Watt JP, Santosham M.</emphasis> 2005. Prevention of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> type b disease: past success and future challenges. <citetitle><emphasis>Expert Rev Vaccines</emphasis></citetitle> <emphasis role="strong">4:</emphasis>819–827.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Ribeiro GS, Lima JB, Reis JN, Gouveia EL, Cordeiro SM, Lobo TS, Pinheiro RM, Ribeiro CT, Neves AB, Salgado K, Silva HR, Reis MG, Ko AI.</emphasis> 2007. <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> meningitis 5 years after introduction of the <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> type b conjugate vaccine in Brazil. <citetitle><emphasis>Vaccine</emphasis></citetitle> <emphasis role="strong">25:</emphasis>4420–4428.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Saha SK, Darmstadt GL, Baqui AH, Islam N, Qazi S, Islam M, El Arifeen S, Santosham M, Black RE, Crook DW.</emphasis> 2008. Direct detection of the multidrug resistance genome of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> in cerebrospinal fluid of children: implications for treatment of meningitis. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">27:</emphasis>49–53.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Quentin R, Musser JM, Mellouet M, Sizaret PY, Selander RK, Goudeau A.</emphasis> 1989. Typing of urogenital, maternal, and neonatal isolates of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> and <citetitle><emphasis>Haemophilus parainfluenzae</emphasis></citetitle> in correlation with clinical source of isolation and evidence for a genital specificity of <citetitle><emphasis>H. influenzae</emphasis></citetitle> biotype IV. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">27:</emphasis>2286–2294.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Wallace RJ Jr, Baker CJ, Quinones FJ, Hollis DG, Weaver RE, Wiss K.</emphasis> 1983. Nontypable <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> (biotype 4) as a neonatal, maternal, and genital pathogen. <citetitle><emphasis>Rev Infect Dis</emphasis></citetitle> <emphasis role="strong">5:</emphasis>123–136.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Murphy TF, Sethi S.</emphasis> 2002. Chronic obstructive pulmonary disease: role of bacteria and guide to antibacterial selection in the older patient. <citetitle><emphasis>Drugs Aging</emphasis></citetitle> <emphasis role="strong">19:</emphasis>761–775.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Sethi S, Murphy TF.</emphasis> 2001. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">14:</emphasis>336–363.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Czelusta A, Yen-Moore A, Van der Straten M, Carrasco D, Tyring SK.</emphasis> 2000. An overview of sexually transmitted diseases. Part III. Sexually transmitted diseases in HIV-infected patients. <citetitle><emphasis>J Am Acad Dermatol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>409–432, quiz 433–436.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">DiCarlo RP, Martin DH.</emphasis> 1997. The clinical diagnosis of genital ulcer disease in men. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">25</emphasis><emphasis role="strong">:</emphasis>292–298.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Mohammed TT, Olumide YM.</emphasis> 2008. Chancroid and human immunodeficiency virus infection—a review. <citetitle><emphasis>Int J Dermatol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>1–8.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Zaretzky FR, Kawula TH.</emphasis> 1999. Examination of early interactions between <citetitle><emphasis>Haemophilus ducreyi</emphasis></citetitle> and host cells by using cocultured HaCaT keratinocytes and foreskin fibroblasts. <citetitle><emphasis>Infect Immun</emphasis></citetitle> <emphasis role="strong">67:</emphasis>5352–5360.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Mitjà O, Lukehart SA, Pokowas G, Moses P, Kapa A, Godornes C, Robson J, Cherian S, Houinei W, Kazadi W, Siba P, de Lazzari E, Bassat Q.</emphasis> 2014. <citetitle><emphasis>Haemophilus ducreyi</emphasis></citetitle> as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study. <citetitle><emphasis>Lancet Glob Health</emphasis></citetitle> <emphasis role="strong">2:</emphasis>e235–e241.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Centers for Disease Control and Prevention National Center for HIV/AIDS,</emphasis> Viral Hepatitis, STD, and TB Prevention, Division of STD Prevention<emphasis role="strong">.</emphasis> 2010. Sexually transmitted disease surveillance.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Pittman M, Davis DJ.</emphasis> 1950. Identification of the Koch-Weeks bacillus (<citetitle><emphasis>Hemophilus aegyptius</emphasis></citetitle>). <citetitle><emphasis>J Bacteriol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>413–426.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Barbosa SF, Hoshino-Shimizu S, Alkmin M, Goto H.</emphasis> 2003. Implications of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> biogroup aegyptius hemagglutinins in the pathogenesis of Brazilian purpuric fever. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">188:</emphasis>74–80.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Brandileone MC, Ajello GW, Bibb WF, Vieira VS, Sottnek FO, Swaminathan B, The Brazilian Purpuric Fever Study Group.</emphasis> 1989. Development of diagnostic tests for <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> biogroup aegyptius, the etiologic agent of Brazilian purpuric fever. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">8:</emphasis>243–245.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Albritton WL.</emphasis> 1982. Infections due to <citetitle><emphasis>Haemophilus</emphasis></citetitle> species other than <citetitle><emphasis>H. influenzae. Annu Rev Microbiol</emphasis></citetitle> <emphasis role="strong">36</emphasis><emphasis role="strong">:</emphasis>199–216.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey B, Wagener J.</emphasis> 1999. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. <citetitle><emphasis>Pediatr Pulmonol</emphasis></citetitle> <emphasis role="strong">28:</emphasis>321–328.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Dangor Y, Radebe F, Ballard RC.</emphasis> 1993. Transport media for <citetitle><emphasis>Haemophilus ducreyi. Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">20:</emphasis>5–9.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Lewis AL.</emphasis> 2016. <citetitle><emphasis>Haemophilus ducreyi</emphasis></citetitle> cultures. <citetitle><emphasis>In</emphasis></citetitle> Leber AL (ed), <citetitle><emphasis>Clinical Microbiology Procedures Handbook</emphasis></citetitle>, vol 1. ASM Press, Washington, DC.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Mein J, Lum G.</emphasis> 1999. CSF bacterial antigen detection tests offer no advantage over Gram’s stain in the diagnosis of bacterial meningitis. <citetitle><emphasis>Pathology</emphasis></citetitle> <emphasis role="strong">31:</emphasis>67–69.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Poppert S, Essig A, Stoehr B, Steingruber A, Wirths B, Juretschko S, Reischl U, Wellinghausen N.</emphasis> 2005. Rapid diagnosis of bacterial meningitis by real-time PCR and fluorescence in situ hybridization. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>3390–3397.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Chiba N, Murayama SY, Morozumi M, Nakayama E, Okada T, Iwata S, Sunakawa K, Ubukata K.</emphasis> 2009. Rapid detection of eight causative pathogens for the diagnosis of bacterial meningitis by real-time PCR. <citetitle><emphasis>J Infect Chemother</emphasis></citetitle> <emphasis role="strong">15:</emphasis>92–98.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Corless CE, Guiver M, Borrow R, Edwards-Jones V, Fox AJ, Kaczmarski EB.</emphasis> 2001. Simultaneous detection of <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle>, <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle>, and <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle> in suspected cases of meningitis and septicemia using real-time PCR. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>1553–1558.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0054" role="bibliographyEntry">
            <anchor id="ch0054s0019s0002a0004"/>
            <para>54.<emphasis role="strong">Tzanakaki G, Tsopanomichalou M, Kesanopoulos K, Matzourani R, Sioumala M, Tabaki A, Kremastinou J.</emphasis> 2005. Simultaneous single-tube PCR assay for the detection of <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle>, <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> type b and <citetitle><emphasis>Streptococcus pneumoniae. Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">11:</emphasis>386–390.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Dangor Y, Ballard RC, da L Exposto F, Fehler G, Miller SD, Koornhof HJ.</emphasis> 1990. Accuracy of clinical diagnosis of genital ulcer disease. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>184–189.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Lewis DA.</emphasis> 2000. Diagnostic tests for chancroid. <citetitle><emphasis>Sex Transm Infect</emphasis></citetitle> <emphasis role="strong">76:</emphasis>137–141.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Morse SA, Trees DL, Htun Y, Radebe F, Orle KA, Dangor Y, Beck-Sague CM, Schmid S, Fehler G, Weiss JB, Ballard RC.</emphasis> 1997. Comparison of clinical diagnosis and standard laboratory and molecular methods for the diagnosis of genital ulcer disease in Lesotho: association with human immunodeficiency virus infection. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">175:</emphasis>583–589.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">West B, Wilson SM, Changalucha J, Patel S, Mayaud P, Ballard RC, Mabey D.</emphasis> 1995. Simplified PCR for detection of <citetitle><emphasis>Haemophilus ducreyi</emphasis></citetitle> and diagnosis of chancroid. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>787–790.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Kühn C, Disqué C, Mühl H, Orszag P, Stiesch M, Haverich A.</emphasis> 2011. Evaluation of commercial universal rRNA gene PCR plus sequencing tests for identification of bacteria and fungi associated with infectious endocarditis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>2919–2923.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Wu HM, Cordeiro SM, Harcourt BH, Carvalho M, Azevedo J, Oliveira TQ, Leite MC, Salgado K, Reis MG, Plikaytis BD, Clark TA, Mayer LW, Ko AI, Martin SW, Reis JN.</emphasis> 2013. Accuracy of real-time PCR, Gram stain and culture for <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle>, <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> and <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> meningitis diagnosis. <citetitle><emphasis>BMC Infect</emphasis></citetitle> <citetitle><emphasis>Dis</emphasis></citetitle> <emphasis role="strong">13:</emphasis>26.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Abdeldaim GM, Herrmann B.</emphasis> 2013. PCR detection of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> from respiratory specimens. <citetitle><emphasis>Methods Mol Biol</emphasis></citetitle> <emphasis role="strong">943:</emphasis>115–123.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Abdeldaim GM, Strålin K, Kirsebom LA, Olcén P, Blomberg J, Herrmann B.</emphasis> 2009. Detection of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> in respiratory secretions from pneumonia patients by quantitative real-time polymerase chain reaction. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">64:</emphasis>366–373.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Abdeldaim GM, Strålin K, Olcén P, Blomberg J, Mölling P, Herrmann B.</emphasis> 2013. Quantitative <citetitle><emphasis>fucK</emphasis></citetitle> gene polymerase chain reaction on sputum and nasopharyngeal secretions to detect <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> pneumonia. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">76:</emphasis>141–146.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Graf EH, Farquharson MV, Cárdenas AM.</emphasis> 2017. Comparative evaluation of the FilmArray meningitis/encephalitis molecular panel in a pediatric population. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">87:</emphasis>92–94.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Hanson KE, Slechta ES, Killpack JA, Heyrend C, Lunt T, Daly JA, Hemmert AC, Blaschke AJ.</emphasis> 2016. Preclinical assessment of a fully automated multiplex PCR panel for detection of central nervous system pathogens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>785–787.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Leber AL, Everhart K, Balada-Llasat JM, Cullison J, Daly J, Holt S, Lephart P, Salimnia H, Schreckenberger PC, DesJarlais S, Reed SL, Chapin KC, LeBlanc L, Johnson JK, Soliven NL, Carroll KC, Miller JA, Dien Bard J, Mestas J, Bankowski M, Enomoto T, Hemmert AC, Bourzac KM.</emphasis> 2016. Multicenter evaluation of BioFire FilmArray meningitis/encephalitis panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>2251–2261.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Messacar K, Breazeale G, Robinson CC, Dominguez SR.</emphasis> 2016. Potential clinical impact of the film array meningitis encephalitis panel in children with suspected central nervous system infections. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">86:</emphasis>118–120.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Liesman RM, Strasburg AP, Heitman AK, Theel ES, Patel R, Binnicker MJ.</emphasis> 2018. Evaluation of a commercial multiplex molecular panel for diagnosis of infectious meningitis and encephalitis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>e01927-17.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Schoenmakers JWA, de Boer R, Gard L, Kampinga GA, van Oosten M, van Dijl JM, Jutte PC, Wouthuyzen-Bakker M.</emphasis> 2023. First evaluation of a commercial multiplex PCR panel for rapid detection of pathogens associated with acute joint infections. <citetitle><emphasis>J Bone Jt Infect</emphasis></citetitle> <emphasis role="strong">8:</emphasis>45–50.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Saeed K, Ahmad-Saeed N, Annett R, Barlow G, Barrett L, Boyd SE, Boran N, Davies P, Hughes H, Jones G, Leach L, Lynch M, Nayar D, Maloney RJ, Marsh M, Milburn O, Mitchell S, Moffat L, Moore LSP, Murphy ME, O’Shea SA, O’Sullivan F, Peach T, Petridou C, Reidy N, Selvaratnam M, Talbot B, Taylor V, Wearmouth D, Aldridge C.</emphasis> 2023. A multicentre evaluation and expert recommendations of use of the newly developed BioFire Joint Infection polymerase chain reaction panel. <citetitle><emphasis>Eur J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42</emphasis><emphasis role="strong">:</emphasis>169–176.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Azad MA, Wolf MJ, Strasburg AP, Daniels ML, Starkey JC, Donadio AD, Abdel MP, Greenwood-Quaintance KE, Patel R.</emphasis> 2022. Comparison of the BioFire Joint Infection Panel to 16S Ribosomal RNA Gene-Based Targeted Metagenomic Sequencing for Testing Synovial Fluid from Patients with Knee Arthroplasty Failure. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">60</emphasis><emphasis role="strong">:</emphasis>e0112622.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Murphy CN, Fowler R, Balada-Llasat JM, Carroll A, Stone H, Akerele O, Buchan B, Windham S, Hopp A, Ronen S, Relich RF, Buckner R, Warren DA, Humphries R, Campeau S, Huse H, Chandrasekaran S, Leber A, Everhart K, Harrington A, Kwong C, Bonwit A, Dien Bard J, Naccache S, Zimmerman C, Jones B, Rindlisbacher C, Buccambuso M, Clark A, Rogatcheva M, Graue C, Bourzac KM.</emphasis> 2020. Multicenter evaluation of the BioFire FilmArray Pneumonia/Pneumonia Plus panel for detection and quantification of agents of lower respiratory tract infection. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>e00128-20.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Klein M, Bacher J, Barth S, Atrzadeh F, Siebenhaller K, Ferreira I, Beisken S, Posch AE, Carroll KC, Wunderink RG, Qi C, Wu F, Hardy DJ, Patel R, Sims MD.</emphasis> 2021. Multicenter evaluation of the Unyvero platform for testing bronchoalveolar lavage fluid. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>e02497-20.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">McLinn SE, Nelson JD, Haltalin KC.</emphasis> 1970. Antimicrobial susceptibility of <citetitle><emphasis>Hemophilus influenzae. Pediatrics</emphasis></citetitle> <emphasis role="strong">45</emphasis><emphasis role="strong">:</emphasis>827–838.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Catlin BW.</emphasis> 1970. <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> in cultures of cerebrospinal fluid. Noncapsulated variants typable by immunofluorescence. <citetitle><emphasis>Am J Dis Child</emphasis></citetitle> <emphasis role="strong">120:</emphasis>203–210.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Pittman M.</emphasis> 1931. Variation and type-specificity in the bacterial species, <citetitle><emphasis>Haemophilus influenzae. J Exp Med</emphasis></citetitle> <emphasis role="strong">53</emphasis><emphasis role="strong">:</emphasis>471–492.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Rennie R, Gordon T, Yaschuk Y, Tomlin P, Kibsey P, Albritton W.</emphasis> 1992. Laboratory and clinical evaluations of media for the primary isolation of <citetitle><emphasis>Haemophilus</emphasis></citetitle> species. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">30:</emphasis>1917–1921.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Chapin KC, Doern GV.</emphasis> 1983. Selective media for recovery of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> from specimens contaminated with upper respiratory tract microbial flora. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">17:</emphasis>1163–1165.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Doern GV, Brogden-Torres B.</emphasis> 1992. Optimum use of selective plated media in primary processing of respiratory tract specimens from patients with cystic fibrosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">30:</emphasis>2740–2742.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Fuller DD, Davis TE, Kibsey PC, Rosmus L, Ayers LW, Ott M, Saubolle MA, Sewell DL.</emphasis> 1994. Comparison of BACTEC Plus 26 and 27 media with and without fastidious organism supplement with conventional methods for culture of sterile body fluids. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">32:</emphasis>1488–1491.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Bourbeau P, Riley J, Heiter BJ, Master R, Young C, Pierson C.</emphasis> 1998. Use of the BacT/Alert blood culture system for culture of sterile body fluids other than blood. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>3273–3277.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Doern GV, Chapin KC.</emphasis> 1984. Laboratory identification of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle>: effects of basal media on the results of the satellitism test and evaluation of the RapID NH system. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">20:</emphasis>599–601.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Evans NM, Smith DD.</emphasis> 1972. The effect of the medium and source of growth factors on the satellitism test for <citetitle><emphasis>Haemophilus</emphasis></citetitle> species. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">5:</emphasis>509–514.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Biberstein EL, Mini PD, Gills MG.</emphasis> 1963. Action of <citetitle><emphasis>Haemophilus</emphasis></citetitle> cultures on delta-aminolevulinic acid. <citetitle><emphasis>J Bacteriol</emphasis></citetitle> <emphasis role="strong">86:</emphasis>814–819.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Kilian M.</emphasis> 1974. A rapid method for the differentiation of <citetitle><emphasis>Haemophilus</emphasis></citetitle> strains. The porphyrin test. <citetitle><emphasis>Acta Pathol Microbiol Scand B Microbiol Immunol</emphasis></citetitle> <emphasis role="strong">82:</emphasis>835–842.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0086" role="bibliographyEntry">
            <anchor id="ch0054s0019s0002a0005"/>
            <para>86.<emphasis role="strong">Munson E, Pfaller M, Koontz F, Doern G.</emphasis> 2002. Comparison of porphyrin-based, growth factor-based, and biochemical-based testing methods for identification of <citetitle><emphasis>Haemophilus influenzae. Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">21:</emphasis>196–203.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Valenza G, Ruoff C, Vogel U, Frosch M, Abele-Horn M.</emphasis> 2007. Microbiological evaluation of the new VITEK 2 <citetitle><emphasis>Neisseria</emphasis></citetitle>-<citetitle><emphasis>Haemophilus</emphasis></citetitle> identification card. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>3493–3497.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Rennie RP, Brosnikoff C, Shokoples S, Reller LB, Mirrett S, Janda W, Ristow K, Krilcich A.</emphasis> 2008. Multicenter evaluation of the new Vitek 2 <citetitle><emphasis>Neisseria</emphasis></citetitle>-<citetitle><emphasis>Haemophilus</emphasis></citetitle> identification card. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>2681–2685.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Couturier MR, Mehinovic E, Croft AC, Fisher MA.</emphasis> 2011. Identification of HACEK clinical isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>1104–1106.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">van Veen SQ, Claas EC, Kuijper EJ.</emphasis> 2010. High-throughput identification of bacteria and yeast by matrix-assisted laser desorption ionization-time of flight mass spectrometry in conventional medical microbiology laboratories. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>900–907.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Branda JA, Rychert J, Burnham CA, Bythrow M, Garner OB, Ginocchio CC, Jennemann R, Lewinski MA, Manji R, Mochon AB, Procop GW, Richter SS, Sercia LF, Westblade LF, Ferraro MJ.</emphasis> 2014. Multicenter validation of the VITEK MS v2.0 MALDI-TOF mass spectrometry system for the identification of fastidious gram-negative bacteria. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">78:</emphasis>129–131.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Powell EA, Blecker-Shelly D, Montgomery S, Mortensen JE.</emphasis> 2013. Application of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of the fastidious pediatric pathogens <citetitle><emphasis>Aggregatibacter</emphasis></citetitle>, <citetitle><emphasis>Eikenella</emphasis></citetitle>, <citetitle><emphasis>Haemophilus</emphasis></citetitle>, and <citetitle><emphasis>Kingella. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>3862–3864.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Nürnberg S, Claus H, Krone M, Vogel U, Lâm TT.</emphasis> 2020. Discriminative potential of the Vitek MS <citetitle><emphasis>in vitro</emphasis></citetitle> diagnostic device regarding <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> and <citetitle><emphasis>Haemophilus haemolyticus. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>e00278-20.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Frickmann H, Christner M, Donat M, Berger A, Essig A, Podbielski A, Hagen RM, Poppert S.</emphasis> 2013. Rapid discrimination of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle>, <citetitle><emphasis>H. parainfluenzae</emphasis></citetitle>, and <citetitle><emphasis>H. haemolyticus</emphasis></citetitle> by fluorescence in situ hybridization (FISH) and two matrix-assisted laser-desorption-ionization time-of-flight mass spectrometry (MALDI-TOF-MS) platforms. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e63222.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Martiny D, Busson L, Wybo I, El Haj RA, Dediste A, Vanenberg O.</emphasis> 2012. Comparison of the Microflex LT and Vitek MS systems for routine identification of bacteria by matrix-assisted laser desorption ionization-time of flight mass spectrometry. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>1313–1325.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Månsson V, Resman F, Kostrzewa M, Nilson B, Riesbeck K.</emphasis> 2015. Identification of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> type b isolates by use of matrix-assisted laser desorption ionization–time of flight mass spectrometry. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>2215–2224.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Clarridge JE III.</emphasis> 2004. Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. <citetitle><emphasis>Clin Microbi</emphasis></citetitle><citetitle><emphasis>ol Rev</emphasis></citetitle> <emphasis role="strong">17:</emphasis>840–862.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Parsons LM, Shayegani M, Waring AL, Bopp LH.</emphasis> 1989. DNA probes for the identification of <citetitle><emphasis>Haemophilus ducreyi. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">27:</emphasis>1441–1445.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Woo PC, Ng KH, Lau SK, Yip KT, Fung AM, Leung KW, Tam DM, Que TL, Yuen KY.</emphasis> 2003. Usefulness of the MicroSeq 500 16S ribosomal DNA-based bacterial identification system for identification of clinically significant bacterial isolates with ambiguous biochemical profiles. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>1996–2001.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Marty A, Greiner O, Day PJ, Gunziger S, Mühlemann K, Nadal D.</emphasis> 2004. Detection of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> type b by real-time PCR. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>3813–3815.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Ohkusu K, Nash KA, Inderlied CB.</emphasis> 2005. Molecular characterisation of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> type a and untypeable strains isolated simultaneously from cerebrospinal fluid and blood: novel use of quantitative real-time PCR based on the cap copy number to determine virulence. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">11:</emphasis>637–643.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Strålin K, Bäckman A, Holmberg H, Fredlund H, Olcén P.</emphasis> 2005. Design of a multiplex PCR for <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle>, <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle>, <citetitle><emphasis>Mycoplasma pneumoniae</emphasis></citetitle> and <citetitle><emphasis>Chlamydophila pneumoniae</emphasis></citetitle> to be used on sputum samples. <citetitle><emphasis>APMIS</emphasis></citetitle> <emphasis role="strong">113:</emphasis>99–111.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Wellinghausen N, Wirths B, Franz AR, Karolyi L, Marre R, Reischl U.</emphasis> 2004. Algorithm for the identification of bacterial pathogens in positive blood cultures by real-time LightCycler polymerase chain reaction (PCR) with sequence-specific probes. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">48:</emphasis>229–241.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Kais M, Spindler C, Kalin M, Ortqvist A, Giske CG.</emphasis> 2006. Quantitative detection of <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle>, <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle>, and <citetitle><emphasis>Moraxella catarrhalis</emphasis></citetitle> in lower respiratory tract samples by real-time PCR. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">55:</emphasis>169–178.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Cattoir V, Lemenand O, Avril JL, Gaillot O.</emphasis> 2006. The sodA gene as a target for phylogenetic dissection of the genus <citetitle><emphasis>Haemophilus</emphasis></citetitle> and accurate identification of human clinical isolates. <citetitle><emphasis>Int J Med Microbiol</emphasis></citetitle> <emphasis role="strong">296:</emphasis>531–540.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">van Ketel RJ, de Wever B, van Alphen L.</emphasis> 1990. Detection of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> in cerebrospinal fluids by polymerase chain reaction DNA amplification. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>271–276.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Buchan BW, Ginocchio CC, Manii R, Cavagnolo R, Pancholi P, Swyers L, Thomson RB Jr, Anderson C, Kaul K, Ledeboer NA.</emphasis> 2013. Multiplex identification of gram-positive bacteria and resistance determinants directly from positive blood culture broths: evaluation of an automated microarray-based nucleic acid test. <citetitle><emphasis>PLoS Med</emphasis></citetitle> <emphasis role="strong">10:</emphasis>e1001478.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Salimnia H, Fairfax MR, Lephart PR, Schreckenberger P, DesJarlais SM, Johnson JK, Robinson G, Carroll KC, Greer A, Morgan M, Chan R, Loeffelholz M, Valencia-Shelton F, Jenkins S, Schuetz AN, Daly JA, Barney T, Hemmert A, Kanack KJ.</emphasis> 2016. Evaluation of the FilmArray blood culture identification panel: results of a multicenter controlled trial. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>687–698.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Holma T, Torvikoski J, Friberg N, Nevalainen A, Tarkka E, Antikainen J, Martelin JJ.</emphasis> 2022. Rapid molecular detection of pathogenic microorganisms and antimicrobial resistance markers in blood cultures: evaluation and utility of the next-generation FilmArray Blood Culture Identification 2 panel. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">41:</emphasis>363–371.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Wolk DM, Young S, Whitfield NN, Reid JL, Thornberg A, Carroll KC, Buchan BW, Davis TE, Salimnia H.</emphasis> 2021. A multicenter clinical study to demonstrate the diagnostic accuracy of the GenMark Dx ePlex blood culture identification Gram-negative panel. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>e02484-20.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">LaClaire LL, Tondella ML, Beall DS, Noble CA, Raghunathan PL, Rosenstein NE, Popovic T, Active Bacterial Core Surveillance Team Members.</emphasis> 2003. Identification of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> serotypes by standard slide agglutination serotyping and PCR-based capsule typing. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>393–396.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Sell SH, Sanders RS, Cheatham WJ.</emphasis> 1963. <citetitle><emphasis>Hemophilus influenzae</emphasis></citetitle> in respiratory infections. II. Specific serological antibodies identified by agglutination and immunofluorescent techniques. <citetitle><emphasis>Am J Dis Child</emphasis></citetitle> <emphasis role="strong">105:</emphasis>470–474.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Harrison OB, Brueggemann AB, Caugant DA, van der Ende A, Frosch M, Gray S, Heuberger S, Krizova P, Olcen P, Slack M, Taha MK, Maiden MCJ.</emphasis> 2011. Molecular typing methods for outbreak detection and surveillance of invasive disease caused by <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle>, <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> and <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle>, a review. <citetitle><emphasis>Microbiol (Reading)</emphasis></citetitle> <emphasis role="strong">157:</emphasis>2181–2195.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Maaroufi Y, De Bruyne JM, Heymans C, Crokaert F.</emphasis> 2007. Real-time PCR for determining capsular serotypes of <citetitle><emphasis>Haemophilus influenzae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>2305–2308.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Aparicio P, Román F, Campos J.</emphasis> 1996. [Epidemiological characterization of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> using molecular markers]. <citetitle><emphasis>Enferm Infecc Microbiol Clin</emphasis></citetitle> <emphasis role="strong">14:</emphasis>227–232.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Bruant G, Watt S, Quentin R, Rosenau A.</emphasis> 2003. Typing of nonencapsulated <citetitle><emphasis>Haemophilus</emphasis></citetitle> strains by repetitive-element sequence-based PCR using intergenic dyad sequences. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>3473–3480.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Saito M, Umeda A, Yoshida S.</emphasis> 1999. Subtyping of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> strains by pulsed-field gel electrophoresis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>2142–2147.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Power PM, Bentley SD, Parkhill J, Moxon ER, Hood DW.</emphasis> 2012. Investigations into genome diversity of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> using whole genome sequencing of clinical isolates and laboratory transformants. <citetitle><emphasis>BMC Microbiol</emphasis></citetitle> <emphasis role="strong">12:</emphasis>273.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">De Chiara M, Hood D, Muzzi A, Pickard DJ, Perkins T, Pizza M, Dougan G, Rappuoli R, Moxon ER, Soriani M, Donati C.</emphasis> 2014. Genome sequencing of disease and carriage isolates of nontypeable <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> identifies discrete population structure. <citetitle><emphasis>Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">111:</emphasis>5439–5444.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Staples M, Graham RMA, Jennison AV.</emphasis> 2017. Characterisation of invasive clinical <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> isolates in Queensland, Australia using whole-genome sequencing. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">145:</emphasis>1727–1736.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Månsson V, Skaare D, Riesbeck K, Resman F.</emphasis> 2017. The spread and clinical impact of ST14CC-PBP3 type IIb/A, a clonal group of non-typeable <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> with chromosomally mediated β-lactam resistance—a prospective observational study. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">23:</emphasis>209.e1–209.e7.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Burman LA, Leinonen M, Trollfors B.</emphasis> 1994. Use of serology to diagnose pneumonia caused by nonencapsulated <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> and <citetitle><emphasis>Moraxella catarrhalis. J Infect Dis</emphasis></citetitle> <emphasis role="strong">170:</emphasis>220–222.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Strålin K, Holmberg H, Olcén P.</emphasis> 2004. Antibody response to the patient’s own <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> isolate can support the aetiology in lower respiratory tract infections. <citetitle><emphasis>APMIS</emphasis></citetitle> <emphasis role="strong">112:</emphasis>299–303.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Jacobs MR, Anon J, Appelbaum PC.</emphasis> 2004. Mechanisms of resistance among respiratory tract pathogens. <citetitle><emphasis>Clin Lab Med</emphasis></citetitle> <emphasis role="strong">24:</emphasis>419–453.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">CLSI.</emphasis> 2021. <citetitle><emphasis>Performance Standards for Antimicrobial Susceptibility Testing; 31st Informational Supplement. CLSI Document M100-S31.</emphasis></citetitle> Clinical and Laboratory Standards Institute, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Heilmann KP, Rice CL, Miller AL, Miller NJ, Beekmann SE, Pfaller MA, Richter SS, Doern GV.</emphasis> 2005. Decreasing prevalence of beta-lactamase production among respiratory tract isolates of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> in the United States. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">49:</emphasis>2561–2564.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Pichichero ME.</emphasis> 2013. Otitis media. <citetitle><emphasis>Pediatr Clin North Am</emphasis></citetitle> <emphasis role="strong">60:</emphasis>391–407.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Pfaller MA, Farrell DJ, Sader HS, Jones RN.</emphasis> 2012. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle>, <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle>, and <citetitle><emphasis>Moraxella catarrhalis</emphasis></citetitle> in the United States. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">55</emphasis>(Suppl 3)<emphasis role="strong">:</emphasis>S187–S193.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0129" role="bibliographyEntry">
            <para>129.<emphasis role="strong">Ishiwada N, Fujimaki K, Matsumoto T, Kiyota H, Tateda K, Sato J, Hanaki H, Takayanagi R, Yamaguchi Y, Hoshino T, Kuroki H, Iwata S, Tajima T, Horikoshi Y, Shiro H, Bamba M, Kawamura N, Ouchi K, Matsubara K, Okada T, Furuno K, Tsumura N.</emphasis> 2021. Nationwide surveillance of bacterial pathogens isolated from children conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2017: general overview of pathogenic antimicrobial susceptibility. <citetitle><emphasis>J Infect Chemother</emphasis></citetitle> <emphasis role="strong">27:</emphasis>139–150.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Pfaller MA, Huband MD, Shortridge D, Flamm RK.</emphasis> 2021. Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019. <citetitle><emphasis>J Glob Antimicrob Resist</emphasis></citetitle> <emphasis role="strong">27:</emphasis>337–351.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Sader HS, Carvalhaes CG, Duncan LR, Shortridge D.</emphasis> 2020. Antimicrobial activity of ceftolozane-tazobactam and comparators against clinical isolates of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> from the United States and Europe. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">64:</emphasis>e00211-20.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Markowitz SM.</emphasis> 1980. Isolation of an ampicillin-resistant, non-beta-lactamase-producing strain of <citetitle><emphasis>Haemophilus influenzae. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">17:</emphasis>80–83.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Kaczmarek FS, Gootz TD, Dib-Hajj F, Shang W, Hallowell S, Cronan M.</emphasis> 2004. Genetic and molecular characterization of beta-lactamase-negative ampicillin-resistant <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> with unusually high resistance to ampicillin. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">48:</emphasis>1630–1639.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Ubukata K, Shibasaki Y, Yamamoto K, Chiba N, Hasegawa K, Takeuchi Y, Sunakawa K, Inoue M, Konno M.</emphasis> 2001. Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant <citetitle><emphasis>Haemophilus influenzae. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">45:</emphasis>1693–1699.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Fluit AC, Florijn A, Verhoef J, Milatovic D.</emphasis> 2005. Susceptibility of European beta-lactamase-positive and -negative <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> isolates from the periods 1997/1998 and 2002/2003. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>133–138.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">Sader HS, Flamm RK, Streit JM, Carvalhaes CG, Mendes RE.</emphasis> 2018. Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America. <citetitle><emphasis>Int J Infect Dis</emphasis></citetitle> <emphasis role="strong">77:</emphasis>82–86.</para>
          </listitem>
          <listitem id="ch0054s0019s0002li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">CLSI.</emphasis> 2018. <citetitle><emphasis>Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically (Approved Standard)</emphasis></citetitle>, 11th ed. CLSI document M07-A11. Clinical Laboratory Standards Institute, Wayne, PA.</para>
          </listitem>
        </itemizedlist>
        <anchor id="ch0054s0019s0002a0006"/>
        <beginpage pagenum="745"/>
      </sect2>
    </sect1>
  </chapter>
